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Since the 1960’s treatments for Parkinson’s disease (PD) have traditionally been directed
to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic
L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has
resulted in extensive efforts to develop new therapies that work in ways other than
restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic
therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic,
and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron
chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a
detailed account of their success in animal models and their translation to human clinical
trials. We then consider how advances in understanding the mechanisms of PD, genetics,
the possibility that PD may consist of multiple disease states, understanding of the
etiology of PD in non-dopaminergic regions as well as advances in clinical trial design
will be essential for ongoing advances. We conclude that despite the challenges ahead,
patients have much cause for optimism that novel therapeutics that offer better disease
management and/or which slow disease progression are inevitable.
Keywords: Parkinson’s disease, animal models, therapeutics, neurodegeneration, L-Dopa, dyskinesias, dopamine,
gene therapy
INTRODUCTION
As the life expectancy in industrialized countries increases, the
burden of Parkinson’s disease (PD) and the associated economic
costs continues to rise, resulting in a dramatic need for effective
treatments. Since the 1960’s, treatments have been wholly symp-
tomatic, involving a range of approaches to effectively restore,
mimic, or replace dopamine (DA). While this treatment strat-
egy, primarily through the use of levodopa (L-Dopa), still remains
the most effective method of alleviating the symptoms of PD, its
effectiveness is limited as long-term use is associated with the
development of debilitating hyperkinetic movements including
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid;
MPP+, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; DOPAC, 3,4-Dihydroxyphenylacetic acid; 6-OHDA,
6-hydroxydopamine; AIMs, abnormal involuntary movements; AAV, adeno-
associated virus; AADC, aromatic l-amino acid decarboxylase; ADAGIO,
Attenuation of Disease Progression with Rasagiline Once-daily; BG, basal gan-
glia; Ca2+, calcium; CNS, central nervous system; CDNF, conserved dopamine
neurotrophic factor; COX, cyclooxygenase; DATATOP, Deprenyl and Tocopherol
Antioxidative Therapy of Parkinsonism; DA, dopamine; GDNF, glial derived
neurotrophic factor; GPi, globus pallidus internus; GLP-1, glucagon-like pep-
tide 1; GAD, glutamic acid-decarboxylase; HVA, homovanillic acid; LRRK2,
leucine-rich repeat kinase-2; LIDs, L-Dopa-induced dyskinesias; LFADLDS,
Lang-Fahn Activities of Daily Living Dyskinesia Scale; L-Dopa, LPS, levodopa;
lipopolysaccharide; mGluRs, metabotropic glutamate receptors; NMDA, N-
methyl-D-aspartate; NTN, neurturin; NSAIDs, non-steroidal anti-inflammatory
drugs; NE, norepinephrine; PD, Parkinson’s disease; ROS, reactive oxygen species;
5-HT, serotonin; Na+, sodium; SN, substantia nigra; SNr, substantia nigra pars
reticulata; STN, subthalamic nucleus; TH, tyrosine hydroxylase; UPDRS, Unified
Parkinson’s Disease Rating Scale; VMAT2, vesicular monoamine transporter 2.
chorea, dystonia and athetosis, collectively known as L-Dopa-
induced dyskinesias (LIDs). It is apparent therefore that the
identification of alternative strategies is crucial.
The early success in developing treatment strategies relied on
the early understanding that PD is a DA deficiency disorder.
However, until recently this concept in many ways also con-
strained therapeutic development to a strategy of restoring or
replacing DA signaling. Studies in rodents and in non-human
primates have, however, more recently led to new insights into
the mechanisms underlying PD. Such studies, together with some
early studies of the effects of brain surgery in humans (Kumar
et al., 1998; Burchiel et al., 1999), have been instrumental in sub-
sequently redefining the motor symptoms of PD as the result of
an imbalance of excitatory/inhibitory drive in the direct and indi-
rect pathways of the basal ganglia (BG) (Albin et al., 1989, 1995;
Graybiel, 1990; Gerfen, 1992; Porter et al., 1994; Wullner et al.,
1994; Blandini et al., 2000; Wu et al., 2012) rather than simply
resulting from a depletion of DA in the striatum (Dauer and
Przedborski, 2003). This in turn has led to a shift in therapeu-
tic development strategies away from DA and toward approaches
that work in novel ways to restore the balance of BG signaling
(Figure 1).
As this review will show, there has been progress. This has
resulted in large part due to the ability of animal models to repli-
cate changes in human BG circuits and in turn, provide valuable
tools for testing therapies that work to restore the balance of exci-
tatory/inhibitory drive. Animal models of PD have almost exclu-
sively utilized various toxins such as MPTP, 6-OHDA, reserpine
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FIGURE 1 | Basal ganglia dysfunction in PD. Diagram representing the
normal function of the basal ganglia (left), the changes occurring in PD
(right), and the site of primary action of therapeutic targets discussed in this
review (numbered). Arrows represent the major neurotransmitters of
glutamate (green), GABA (blue) and dopamine (red). Relative thickness of the
arrows indicates level of activity of neurotransmitter. SNpc, substantia nigra
pars compacta; SNr, substantia nigra reticulata; STN, subthalamic nucleus;
MGP, medial globus pallidus; LGP, lateral globus pallidus.
and the pesticide/herbicides paraquat and maneb, to reproduce
the loss of DA neurons that, in turn, leads to altered signaling in
the direct and indirect pathways of the BG. The reader is referred
to a number of excellent reviews on rodent and non-human pri-
mate models of PD (Corasaniti et al., 1998; Przedborski and Vila,
2003; Przedborski et al., 2004; Smeyne and Jackson-Lewis, 2005;
Simola et al., 2007; Thrash et al., 2007; Blandini et al., 2008;
Duty and Jenner, 2011; Jackson-Lewis et al., 2012). Despite their
well-known limitations (Beal, 2010; Potashkin et al., 2011), these
animal models remain the standard for preclinical testing of novel
therapeutics.
In turn, clinical trials have traditionally focused on testing
novel treatment strategies arising from studies in animal models,
addressing the fundamental movement disorders associated with
PD. As we will show throughout this review, efficacy of these treat-
ments is generally measured by the Unified Parkinson’s Disease
Rating Scale (UPDRS), Abnormal Involuntary Movements Scores
(AIMs) as a measure of dyskinesia severity, and clinical and at
home measurement of time spent moving freely versus period of
time spent when medication is not working well and symptoms
are not well controlled i.e., “on/off” time. To some extent these
measures are limiting, as they are, at very least, subjective. More
recently, there have been efforts to develop biomarkers of PD that
may also act as markers of therapeutic benefit, however, these are
in the earliest stages of development (Lewitt et al., 2013; Lin et al.,
2013; Mollenhauer et al., 2013; Parnetti et al., 2013). While clin-
ical trials continue to face significant challenges, perhaps in part
resulting from the limitations of trial design (elaborated in section
Clinical trials), newly discovered therapeutic approaches have in
some cases resulted in encouraging outcomes.
In this review we aim to comprehensively assess the emerg-
ing non-dopaminergic pharmacological treatments of PD. We
focus on the recent successes in translating outcomes of preclin-
ical studies in animal models to clinical trials. The outcome is to
show that there has been progress in identifying novel treatments
to treat PD motor symptoms and LIDs. Meanwhile, as we will
also discuss, efforts directed to understand the degenerative
process and identify neuroprotective therapies in animal models
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is showing slower progress in translating preclinical results to
positive outcomes in humans, potentially reflecting our poorer
understanding of the mechanisms that underpin degeneration.
A summary of treatments that are directed to restore or replace
dopamine such as L-Dopa, DA agonists, monoamine oxidase B
inhibitors, continuous L-Dopa administration strategies, as well
as the use of anticholinergics can be found in Table 1. However,
while they continue to be of great significance as the mainstay of
PD treatment, this review does not further discuss these thera-
pies, as these have been extensively reviewed elsewhere (Hauser,
2009; Miyasaki, 2010; Perez-Lloret and Rascol, 2010; Schapira,
2011; Marsala et al., 2012; Sprenger and Poewe, 2013).
Nor do we discuss the burgeoning area of research focused
on treating the non-motor symptoms of PD, such as depres-
sion, dementia, sleep disorders, sweating, and many others that
can be as debilitating as the motor symptoms. While these non-
motor symptoms of PD are often poorly recognized and are
not treated effectively, recent clinical trials investigating pima-
vanserin as an anti-psychotic in PD (Cummings et al., 2013)
and recent studies investigating the histamine H3 receptor inverse
agonist, pitolisant, in the treatment of excessive daytime sleepi-
ness in PD patients (Clinicaltrials.gov references NCT01036139,
NCT01066442, NCT00642928), suggest that there are increas-
ing efforts in this area. However, an update of efforts to develop
treatment strategies for the non-motor symptoms of PD, while
needed, is beyond the scope of this review. The reader is referred
to a number of previous reviews on this topic (Aarsland et al.,
1999; Burn, 2002; Emre, 2003; Garcia-Borreguero et al., 2003;
Magerkurth et al., 2005).
THE PURSUIT OF NOVEL TREATMENTS
In the following sections, we describe emerging treatments and
the role that the classical PD animal models have played in their
development. We focus only on compounds or therapeutic tar-
gets that have gone through to human testing, and do not discuss
approaches that so far have only been investigated in animals.
For an overview, Table 2 provides a comprehensive summary of
the efficacy of these treatments in animal models, while Table 3
provides a comprehensive summary of the human clinical trials
to date.
ADENOSINE RECEPTOR ANTAGONISTS
Adenosine is a neuromodulator that regulates responses to DA
and other neurotransmitters in areas of the brain that are respon-
sible for motor function and learning and memory (Latini and
Pedata, 2001). Of the four subtypes of adenosine receptors, the
A2A subtype is densely localized in the BG, with the greatest
density found in the striatum. These receptors have been shown
to be co-localized with D2 receptors on enkephalin-expressing
output neurons of the indirect pathway or found as A2A-D2 het-
eromers (Hettinger et al., 2001; Ishiwata et al., 2005; Jenner et al.,
2009; Soriano et al., 2009) and are therefore thought to play an
important role in the regulation of dopaminergic transmission in
the BG. Postmortem studies of PD patients have demonstrated
a 2.95-fold increase in A2A-receptor expression in the putamen
compared to healthy subjects and increased levels in dyski-
netic patients treated with L-Dopa compared to L-Dopa-treated
patients that displayed no dyskinesias (Calon et al., 2004; Varani
et al., 2010).
There have been numerous studies utilizing animal models
of PD to investigate A2A-receptor antagonists as viable thera-
peutics. The A2A antagonists caffeine, theophylline, SCH58261,
DMPX and KF17837 were all shown to inhibit motor deficits such
as catalepsy and decreased locomotion induced by haloperidol
and in models of tardive dyskinesia in rodents (Mandhane et al.,
1997; Bishnoi et al., 2006, 2007; Salamone et al., 2008; Trevitt
et al., 2009). It has also been shown that oral administration of
preladenant and SCH412348 potentiated L-Dopa-induced con-
tralateral rotation behavior in animals lesioned with 6-OHDA.
Further, daily administration of the A2A-receptor antagonist
preladenant inhibited behavioral sensitization induced by L-
Dopa, suggesting that preladenant may reduce the risk of the
development of dyskinesias (Hodgson et al., 2009). The use of
istradefylline (KW-6002) has also been demonstrated to amelio-
rate the hypolocomotion induced by MPTP and reserpine and to
also exert significant anti-cataleptic benefits in the haloperidol
and reserpine models of PD when combined with administra-
tion of L-Dopa (Shiozaki et al., 1999). Furthermore, KW-6002
has demonstrated little or no induction of dyskinesias in L-Dopa-
primed MPTP-treated marmosets (Kanda et al., 1998).
A2A antagonists have also demonstrated a potential neuropro-
tective role in animal models. The use of caffeine in vivo has been
shown to protect dopaminergic neurons in mice treated with the
PD toxins MPTP, paraquat or maneb (Chen et al., 2001; Xu et al.,
2002; Kalda et al., 2006; Singh et al., 2009; Kachroo et al., 2010).
Although caffeine has been shown to act on both A1 and A2A
receptors, it has been suggested that its neuroprotective proper-
ties result primarily through its interaction with A2A, with the
effects of caffeine largely abolished in A2A receptor knockout mice
(El Yacoubi et al., 2000; Huang et al., 2005). A2A antagonists have
also been demonstrated to protect against dopaminergic neuron
loss in the substantia nigra (SN) induced by 6-OHDA in rats in
addition to preventing the functional loss of striatal dopaminer-
gic nerve terminals and gliosis as a result of MPTP treatment in
mice (Ikeda et al., 2002).
Due to the promising results in animal models of PD, the
adenosine A2A receptor antagonist KW-6002 has been investi-
gated in a number of human clinical trials. KW-6002 potentiated
the effects of concomitant low dose L-Dopa treatment with an
improvement in the amount of time spent “on” and no exac-
erbation of dyskinesias in a small Phase I study (Bara-Jimenez
et al., 2003). Subsequently, two large, randomized, double-blind,
placebo-controlled Phase II studies in advanced PD patients
demonstrated significant reductions in the amount of time spent
“off” over a 12 week period (Lewitt et al., 2008; Stacy et al., 2008;
Mizuno and Kondo, 2013). These findings were replicated by a
large Phase III trial in advanced PD patients where KW-6002
treatment resulted in an 0.7 h reduction in daily “off” times, sus-
tained over 12 weeks, and also resulting in increased functional
“on” time (Hauser et al., 2008). Furthermore, this reduction in
“off” time was sustained over long time periods, with patients
displaying improvements from baseline scores up to 1 year later
(Factor et al., 2010). In most of the clinical trials KW-6002
treatment was associated with some increase in “on time with
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Table 1 | Current treatment strategies in clinical use.
Drug class Drug name/route Clinical use Advantages Disadvantages
Levodopa (with Dopa
Decarboxylase inhibitors)
Sinemet, Parcopa, Atamet Monotherapy Increase levels of
endogenous DA
Motor fluctuations
Dyskinesias
COMT Inhibitors Entacapone, Tolcapone Adjunct therapy Decrease metabolism of
L-Dopa
Decrease in daily dose of
L-Dopa required
Increase daily “on” time and
UPDRS scores
Dyskinesias
Diarrhea
Hepatic toxicity (tolcapone)
Dizziness
Insomnia
Nausea
Dopamine agonists Piribedil, Pramipexole,
Pramipexole extended
release, Ropinirole,
Rotigotine, Cabergoline,
Pergolide
Bromocriptine
Monotherapy (younger
patients)
Adjunct therapy
Increase levels of
endogenous DA
Decrease motor symptoms in
early stages of disease
Sedation
Impulse control disorder
Somnolence
Edema
Levodopa, Carbidopa,
Entacapone combination
Stalevo Monotherapy Increase levels of
endogenous DA
Decrease metabolism of
L-Dopa
Dyskinesias may appear sooner
Side effects are the same as for
individual drug classes
MAO-B Inhibitors Rasagiline, Selegiline,
Safinamide
Initial monotherapy
(mild PD patients)
Adjunct therapy
Decrease catabolism of DA
Decrease rate of progression
on UPDRS
Generally well tolerated
Mild nausea
Constipation
Confusion
Continuous L-Dopa Intravenous bolus,
Intravenous infusion,
Intestinal carbidopa/L-Dopa
gel
Monotherapy Decrease pulsatile DA levels
Increase control of on/off
periods
Decrease dyskinesia severity
and duration
Decrease non motor
symptoms (e.g., mood shifts,
dribbling and urinary function
changes)
Large volumes required
(intravenous)
Requires surgery and prosthetic
device
Mechanical problems
Gastronomy complications
Anticholinergics Trihexyphenidyl, Benztropine,
Orphenadrine, Procyclidine,
Biperiden
Monotherapy
Adjunct Therapy
Decrease acetylcholine levels
Decrease tremor
Dry mouth
Blurred vision
Constipation
Nausea
Impaired sweating
Abbreviations: COMT, catechol-O-methyl transferase; DA, dopamine; L-Dopa, levodopa; MAO-B, monoamine oxidase B; UPDRS, Unified Parkinson’s Disease Rating
Scale.
dyskinesias” and the presence of dyskinesias was reported as an
adverse event more often in the KW-6002 groups. While an appli-
cation for KW-6002 as a new PD drug was declined in the United
States by the FDA in 2008 (Kyowa Hakko Kirin Co Ltd, 2008),
KW-6002 was approved in March 2013 in Japan as an adjunct
treatment to L-Dopa for PD (Kyowa Hakko Kirin Co Ltd, 2013).
The effect of the A2A antagonist preladenant was also
investigated in a 12 week Phase II clinical trial in PD patients
experiencing motor fluctuations (Hauser et al., 2011). There
was a significant reduction in “off” time, however, preladenant
treatment also increased total “on” time with dyskinesias and
“on” time with non-troublesome dyskinesias. Those receiving
the highest dose of preladenant also reported an increase in the
amount of time spent “on” with troublesome dyskinesia. A Phase
II open-label follow up trial was then conducted in which patients
received preladenant twice daily for 36 weeks to assess long-term
safety and efficacy. The primary endpoint of adverse events was
reported in 88% of patients, with dyskinesias and constipation
the most common (Factor et al., 2013). Much like KW-6002,
preladenant treatment does not appear to reduce dyskinesias,
however, it remains to be determined if preladenant causes less
dyskinesia than KW-6002.
GLUTAMATE RECEPTOR ANTAGONISTS
There are two main classes of glutamate receptors,
ionotropic and metabotropic. Ionotropic glutamate receptors,
including the N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
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Table 2 | Effects of non-dopaminergic therapies in animal models.
Drug class Subclass Effect in animal models References
Adenosine receptor
antagonists
A2A antagonists
Preladenant,
Istradefylline, SCH58261,
SCH412348, MSX-3
↓ catalepsy in reserpine and haloperidol models
↑ L-Dopa-induced contralateral turning behavior in
6-OHDA model
↓ behavioral sensitization induced by L-Dopa
↑ locomotion in MPTP and reserpine models
↑ survival of DA neurons in 6-OHDA model
↓ striatal DA nerve terminal loss and gliosis in
MPTP model
Mandhane et al., 1997; Kanda et al., 1998;
Shiozaki et al., 1999; Ikeda et al., 2002;
Salamone et al., 2008; Hodgson et al., 2009;
Trevitt et al., 2009
Non-specific
Caffeine, Theophylline,
DMPX
↓ catalepsy in reserpine and haloperidol models
↑ survival of DA neurons in MPTP, paraquat and
maneb models
Mandhane et al., 1997; Chen et al., 2001; Xu
et al., 2002; Bishnoi et al., 2006; Kalda et al.,
2006; Singh et al., 2009; Trevitt et al., 2009;
Kachroo et al., 2010
NMDA Receptor
Antagonists
NMDA Antagonists
MK-801, Amantadine,
Memantine, L-701,324,
SDZ 220-58,
Dextromethorphan, CPP
↓ haloperidol-induced catalepsy
↓ akinesia in reserpine model
↓ parkinsonian symptoms in MPTP model
↑ stepping with contralateral paw in 6-OHDA
model
↑ contralateral circling in 6-OHDA model
↓ dyskinesias in MPTP and 6-OHDA models
↑ DA neuron survival, DA levels in MPTP and
6-OHDA models
↑ efficacy of L-Dopa
Carlsson and Carlsson, 1989; Graham et al.,
1990; Mehta and Ticku, 1990; Loschmann
et al., 1991; Turski et al., 1991; Zuddas et al.,
1992a,b; Lange et al., 1993; Srivastava et al.,
1993; Kaur and Starr, 1995; St-Pierre and
Bedard, 1995; Marin et al., 1996; McAllister,
1996; Kaur et al., 1997; Konieczny et al., 1999;
Dutra et al., 2002; Kelsey et al., 2004;
Armentero et al., 2006
NMDA-NR2B antagonists
Ifenprodil, Traxoprodil,
Co101244
↓ parkinsonian symptoms in MPTP model
↑ efficacy of L-Dopa
↓ haloperidol-induced catalepsy
↓ appearance of LIDs
Blanchet et al., 1999; Nash et al., 2000;
Steece-Collier et al., 2000
AMPA Receptor
Antagonists
NBQX, Perampanel,
Talampanel
↑ contralateral rotations in 6-OHDA model
↓ reserpine-induced muscle rigidity
↑ L-Dopa-induced reversal of motor deficits in
MPTP and 6-OHDA models
↓ LIDs in MPTP model
↓ L-Dopa-induced AIMs
Klockgether et al., 1991; Loschmann et al.,
1991, 1992; Wachtel et al., 1992; Konitsiotis
et al., 2000
Topiramate ↓ LIDs in MPTP model
↓ L-Dopa-induced AIMs in 6-OHDA model
↓ rotarod performance in 6-OHDA model
Silverdale et al., 2005; Kobylecki et al., 2011
Metabotropic
Glutamate
Receptor
Antagonists
Group I Metabotropic
Glutamate Receptor
Antagonists
MPEP, MTEP, LY367386,
Dipraglurant, AFQ056
↓ akinesia in 6-OHDA model
↓ LIDs in 6-OHDA model
↑ survival of DA neurons in 6-OHDA model
↑ striatal DA in 6-OHDA model
Kearney et al., 1997, 1998; Breysse et al.,
2002, 2003; Coccurello et al., 2004; Kachroo
et al., 2005; Vernon et al., 2005, 2007;
Dekundy et al., 2006; Rylander et al., 2009;
Price et al., 2010; Morin et al., 2013a,b
Serotonin Receptor
Agonists
5-HT1A Agonists
8-OH-DPAT
↓ LIDs in 6-OHDA and MPTP models
↓ activity of raphe-striatal neurons and extracellular
DA release in 6-OHDA model
Carta et al., 2007; Munoz et al., 2008;
Lindgren et al., 2010
5-HT1B Agonists
CP-94253
↓ LIDs in 6-OHDA model
↓ activity of raphe-striatal neurons and extracellular
DA release in 6-OHDA model
Carta et al., 2007; Lindgren et al., 2010
5-HT1A/1B Agonists
Eltoprazine
↓ LIDs in 6-OHDA model
↓ LIDs in MPTP model
↓ LIDs in combination with amantadine
Bezard et al., 2013
Adrenergic
Receptor
Antagonists
α2 Receptor Antagonists
Yohimbine, Idazoxan,
Fipamezole
↓ L-Dopa-induced hyperkinesia in 6-OHDA model
↓ expression of AIMs in 6-OHDA model
↓ haloperidol-induced catalepsy
↓ LIDs in MPTP model
Gomez-Mancilla and Bedard, 1993; Henry
et al., 1998, 1999; Fox et al., 2001; Invernizzi
et al., 2003; Savola et al., 2003; Johnston
et al., 2010; Barnum et al., 2012
(Continued)
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Table 2 | Continued
Drug class Subclass Effect in animal models References
↑ “on time” and “on time without disabling
dyskinesia” in MPTP model
Calcium Channel
Blockers
Cav1.3 Channel Blockers
Isradipine
↑ survival of DA nigral neurons in MPTP and
6-OHDA models
↓ degeneration of striatal DA fibers in 6-OHDA
model
↓ development of motor deficits in MPTP model
↓ LIDs and AIMS in 6-OHDA model
Chan et al., 2007, 2010; Schuster et al., 2009;
Ilijic et al., 2011; Kang et al., 2012
Glucagon-like
Peptide 1 Agonists
GLP-1 Analogs
Exendin-4
↑ survival of DA neurons, DA levels in MPTP model
↑ motor function in MPTP model
↑ rescue of DA neurons, DA levels and
apomorphine-induced circling in 6-OHDA and LPS
models
Harkavyi et al., 2008; Li et al., 2009
Iron Chelators Chelators
Desferrioxamine, VK-28,
Clioquinol, M30,
Deferiprone
↑ striatal DA and normal motor behavior in 6-OHDA
model
↑ survival of DA neurons and striatal DA content in
MPTP model
Ben-Shachar et al., 1991, 1992; Lan and Jiang,
1997; Kaur et al., 2003; Shachar et al., 2004;
Youdim et al., 2004; Youdim, 2012; Gal et al.,
2005
Anti-inflammatories Non-selective NSAIDs
Aspirin, Salicylic acid,
Indomethacin
↑ survival of DA neurons in MPTP model
↑ striatal DA in MPTP model
↓ microglial activation and lymphocyte infiltration in
MPTP model
Aubin et al., 1998; Ferger et al., 1999;
Kurkowska-Jastrzebska et al., 2002
Selective COX-2
inhibitors
Meloxicam, Celocoxib
↑ survival of DA neurons in 6-OHDA and MPTP
models
↑ striatal DA in MPTP model
↑ locomotor activity in MPTP model
↓ microglial activation in 6-OHDA model
Teismann and Ferger, 2001; Sanchez-Pernaute
et al., 2004
Gene Therapy Non-Growth Factors
AADC, GAD
↑ DA levels
↑ behavioral recovery in 6-OHDA model
↑ survival of DA neurons and DA levels in 6-OHDA
model
↓ rotation rates in 6-OHDA model
↑ improvement in bradykinesia, gross motor skills,
and tremor in MPTP model
Fan et al., 1998; Leff et al., 1999;
Sanchez-Pernaute et al., 2001; Luo et al., 2002;
Lee et al., 2005; Emborg et al., 2007
Neurotrophic
Factors
GDNF ↑ density of TH positive fibers and DA levels in
6-OHDA and MPTP models
↑ survival of DA neurons and DA levels in 6-OHDA
model
↓ parkinsonism and LIDs in MPTP model
↑ behavioral recovery in 6-OHDA and MPTP
models
Sauer et al., 1995; Tomac et al., 1995; Miyoshi
et al., 1997; Zhang et al., 1997; Gerhardt et al.,
1999; Kirik et al., 2000a,b; Palfi et al., 2002;
Wang et al., 2002; Eslamboli et al., 2003;
Eberling et al., 2009; Johnston et al., 2009
Neurturin ↑ survival of DA neurons and DA levels in 6-OHDA
and MPTP models
↑ density of TH positive fibers
↑ motor function in MPTP model
Rosenblad et al., 1999; Oiwa et al., 2002;
Kordower et al., 2006; Gasmi et al., 2007a,b;
Herzog et al., 2007
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; 6-OHDA, 6-hydroxydopamine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
AIMs, abnormal involuntary movements; AADC, aromatic l-amino acid decarboxylase; DA, dopamine; GDNF, glial derived neurotrophic factor; GAD, glutamic acid-
decarboxylase; LIDs, L-Dopa-induced dyskinesias; L-Dopa, levodopa; LPS, lipopolysaccharide; NMDA, N-methyl-D-aspartate; NSAIDs, non-steroidal anti-inflammatory
drugs; TH, tyrosine hydroxylase.
Kainate subtypes, mediate the majority of fast excitatory trans-
mission throughout the central nervous system (CNS) and
are important for numerous brain functions (Hollmann and
Heinemann, 1994; Dingledine et al., 1999; Niswender and Conn,
2010; Traynelis et al., 2010; Wiltgen et al., 2010; Wright and
Vissel, 2012). The metabotropic glutamate receptors (mGluRs)
are G protein-coupled receptors that are differentially expressed
throughout the BG and consist of eight subtypes (Conn et al.,
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Table 3 | Effects of non-dopaminergic therapies in human clinical trials.
Drug class Drug name Clinical trial results Status References
Adenosine A2A
receptor
antagonists
Istradefylline
(KW-6002)
Effects
↑ time spent “on”
↓ time spent “off”
Adverse events
↑ time spent “on” with dyskinesias
Phase III in progress Bara-Jimenez et al., 2003; Hauser
et al., 2008; Lewitt et al., 2008;
Stacy et al., 2008
Preladenant Effects
↓ time spent “off”
↑ time spent “on” with dyskinesias
↑ time spent “on” with non-troublesome
dyskinesias
Adverse events
↑ time spent “on” with troublesome
dyskinesias
Phase III recruiting Hauser et al., 2011
NMDA
antagonists
Amantadine Effects
↓ dyskinesia severity
↓ motor fluctuations
Benefits may decrease over time
Used in the clinic as
anti-dyskinetic treatment
Verhagen Metman et al., 1998
Memantine Effects
↑ cognitive scores in dementia with Lewy
bodies
↑ improvement of LIDs
↑ improvement in on/off timing
↓ axial motor symptom scores
Phase IV in progress
Approved for other
conditions (Alzheimer’s
disease)
Emre et al., 2010; Varanese et al.,
2010; Moreau et al., 2013
AMPA receptor
antagonists
Perampanel Effects
Well tolerated and safe
Failure to improve “wearing off” times
Phase II complete
Discontinued/withdrawn
Eggert et al., 2010; Lees et al.,
2012
Talampanel More results pending completion of study and
publication
Phase II complete Clinicaltrials.gov reference
numbers
NCT00036296 NCT00108667
NCT00004576
Topiramate Two Phase II trials terminated due to poor
recruitment or cessation of funding
Known Adverse Events
Depression, aggressive behavior, irritability,
psychosis
Phase II recruiting Clinicaltrials.gov reference
numbers
NCT00794313
NCT00296959
NCT01789047
Metabotropic
glutamate
receptor
antagonists
(Group I)
Dipraglurant Effects
↓ dyskinesia severity
↑ time “on” without dyskinesia
↓ time “off”
Adverse events
Vertigo, visual disturbances, “feeling drunk”
Phase II in progress Clinicaltrial.gov reference number
NCT01336088
AFQ056 Effects
↓ LFADLDS scores
↓ AIMs
Adverse events
Worsening of dyskinesias, dizziness, fatigue
Phase II recruiting Berg et al., 2011
Clinicaltrial.gov reference
numbers
NCT01173731
NCT01491529
Serotonin
receptor
agonists
(5-HT1A)
Sarizotan Effects
↓ dyskinesias as measured by AIMS and
UPDRS scores
↑ improvement in “off” time
Adverse events
↑ parkinsonism
Phase II completed
Discontinued/withdrawn
Olanow et al., 2004; Bara-Jimenez
et al., 2005; Goetz et al., 2007
(Continued)
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Table 3 | Continued
Drug class Drug name Clinical trial results Status References
Buspirone Effects
↓ severity of dyskinesias
Phase II completed Bonifati et al., 1994
Mirtazapine Effects
↓ LIDs
Phase II completed Meco et al., 2003
Clozapine
Tandosprione
Aripiprazole
Effects
↓ dyskinesias
Approved for other
conditions
Durif et al., 1997; Kannari et al.,
2002; Durif et al., 2004; Meco
et al., 2009
Adrenergic
receptor
antagonists
Idazoxan Effects
↓ severity of LIDs
Phase II completed Rascol et al., 2001
Fipamezole Effects
↓ LIDs
Adverse events
↑ blood pressure
Phase II completed Lewitt et al., 2012
Clinicaltrials.gov reference
numbers
NCT01149811
NCT01140841
NCT00040209
Calcium channel
blockers
Isradipine Effects
↓ expected incidence of PD
Adverse events
↑ incidence of leg oedema
↓ blood pressure
Dizziness
Phase II recruiting
Approved for other
conditions
Rodnitzky, 1999; Simuni et al.,
2010; Rees et al., 2011
Glucagon-like
peptide 1
agonists
Exendin-4 Effects
↑ motor function
↑ cognitive function
Adverse Events
Weight loss, distortion of taste, L-Dopa dose
failure, increased parkinsonism
Phase II completed Aviles-Olmos et al., 2013
Iron chelators Deferiprone Effects
↓ iron accumulation in SN
↑ motor function
Adverse events
Transient diarrhea, gastritis, transient
headache, slight proctorrhagia
Phase II in progress Devos et al., 2014
Clinicaltrials.gov reference
numbers
NCT01539837
NCT00907283
Anti-
inflammatories
NSAIDS
(non-aspirin)
Effects
No formal clinical studies
↓ risk of developing PD based on
epidemiological studies
Adverse events
↑ risk of gastrointestinal side effects
Meta analysis. No formal
clinical trial
Gagne and Power, 2010
Minocycline Effects
Passed futility threshold of 30% reduction in
UPDRS
No adverse effect on response to symptomatic
therapy
Adverse events
Nausea, upper respiratory symptoms, joint
pain, arthritis
Phase II completed
Approved for other
conditions
NINDS NET-PD Investigators,
2006; NINDS NET-PD
Investigators, 2008
Gene therapy AADC Effects
↑ off medication motor function
↑ AADC activity in striatum
Adverse events
Brain hemorrhage along catheter trajectory
Phase I complete Christine et al., 2009; Muramatsu
et al., 2010
(Continued)
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Table 3 | Continued
Drug class Drug name Clinical trial results Status References
GAD Effects
↑ improvement in UPDRS scores
↓ in UPDRS “off” scores
Phase II complete Kaplitt et al., 2007; Lewitt et al.,
2011
GDNF Effects
No effect on primary outcomes when
administered continuously
Many trials using AAV-GDNF still ongoing
Adverse events
Paresthesias, asymptomatic hyponatremia
Pump infusion—
discontinued/withdrawn
Gene therapy—Phase I
recruiting
Kordower et al., 1999; Nutt et al.,
2003; Slevin et al., 2007
Clinicaltrial.gov reference number
NCT01621581
Neurturin
(CERE-120)
Effects
↓ in UPDRS “off” scores
↑ “on” time without dyskinesias
↓ total “off” time
Deficits in retrograde transport of CERE-120
when administered to putamen
No effect on primary outcomes when
administered in dual locations
Phase II complete Marks et al., 2008, 2010; Bartus
et al., 2011, 2013
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AIMs, abnormal involuntary movements; AAV, adeno-associated virus; AADC, aromatic
l-amino acid decarboxylase; GDNF, glial derived neurotrophic factor; GAD, glutamic acid-decarboxylase; LFADLDS, Lang-Fahn Activities of Daily Living Dyskinesia
Scale; LIDs, L-Dopa-induced dyskinesias; L-Dopa, levodopa; NMDA, N-methyl-D-aspartate; NSAIDs, non-steroidal anti-inflammatory drugs; PD, Parkinson’s disease;
UPDRS, Unified Parkinson’s Disease Rating Scale.
2005; Kuwajima et al., 2007). Unlike ionotropic glutamate
receptors, mGluRs modify neuron membrane potential through
modulating excitatory and inhibitory synaptic transmission by
both pre- and postsynaptic mechanisms (Conn et al., 2005).
Whilst PD has long been known as a condition arising from
a lack of DA-producing neurons, there is a concurrent abnor-
mal release of glutamate in BG circuits, generally considered
a secondary consequence of decreased DA levels. It is thought
that neuronal loss in the SN and consequent striatal DA deple-
tion leads to excessive inhibitory output from the globus pallidus
internus (GPi) and substantia nigra pars reticulata (SNr). This
is due to disinhibition of the subthalamic nucleus (STN), which
drives the GPi and SNr via the release of glutamate (Blandini et al.,
2000). Furthermore, evidence suggests that glutamate-mediated
excitotoxicity may be a primary cause of dopaminergic neuron
loss and therefore aberrant glutamate regulation may also con-
tribute to neurodegeneration in PD (Choi, 1988; Koutsilieri and
Riederer, 2007). Given these observations, attenuating excitatory
drive through antagonizing glutamate receptors may provide a
therapeutic strategy for PD.
NMDA receptors
NMDA receptors are a major subtype of ionotropic glutamate
receptors that are implicated in synaptic plasticity and excitotox-
icity (Vissel et al., 2001; Carroll and Zukin, 2002; Perez-Otano
and Ehlers, 2005; Lau and Zukin, 2007; Hardingham and Bading,
2010; Paoletti et al., 2013). As NMDA receptors are expressed in
neurons of the striatum and STN, excessive activity of the indi-
rect pathway would lead to hyperactivity of these receptors. By
inference, NMDA antagonists would be expected to reduce exces-
sive activation of these receptors in the indirect pathway with
potential therapeutic effects on PD symptoms including reduc-
ing the development and severity of LIDs. In addition, blocking
these receptors may also reduce excitotoxic cell loss and thereby
have disease-modifying actions.
Several NMDA antagonists have been shown to reverse
haloperidol-induced catalepsy and muscle rigidity (Mehta and
Ticku, 1990; McAllister, 1996; Kaur et al., 1997; Konieczny et al.,
1999) and also to reverse akinesia and other motor disturbances
in reserpine-treated rodents (Carlsson and Carlsson, 1989; Kaur
and Starr, 1995; Dutra et al., 2002). These effects have also
been replicated in primate and rodent models of PD. Specifically,
MK-801, a non-competitive NMDA antagonist has been demon-
strated to relieve parkinsonian symptoms in contralateral limbs
when injected unilaterally in MPTP-treated monkeys (Graham
et al., 1990), enhanced stepping with the contralateral paw in
6-OHDA-lesioned rats (Kelsey et al., 2004), and potentiates a
contralateral circling behavior in 6-OHDA-lesioned rats at 4-
fold longer responses than administration of DA alone (St-Pierre
and Bedard, 1995). Interestingly, some NMDA receptor antago-
nists have been shown to potentiate the antiparkinsonian effects
of L-Dopa and reduce the motor complications and dyskinesias
associated with chronic L-Dopa treatment in both rodent and
primate models, suggesting that these drugs may be most useful
in combination with L-Dopa therapy (Loschmann et al., 1991;
Engber et al., 1994; Marin et al., 1996; Blanchet et al., 1999).
NMDA receptors are known to mediate excitotoxic cell death
caused by glutamate, therefore it would be predicted that NMDA
antagonists may slow degeneration of nigral neurons. Consistent
with this, both intranigral infusion and systemic administra-
tion of NMDA receptor antagonists has been shown to protect
nigral dopaminergic neurons when administered either prior to
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or in conjunction with intrastriatal/intranigral injection of 1-
methyl-4-phenylpyridinium (MPP+) in rats (Turski et al., 1991;
Srivastava et al., 1993). Similarly, NMDA receptor antagonists
have been shown to protect against cell death, DA depletion,
and Parkinsonism induced by systemic administration of MPTP
in mice and primates (Zuddas et al., 1992a,b; Lange et al.,
1993). These neuroprotective effects were replicated in 6-OHDA-
lesioned rats with systemic administration of MK-801 reducing
cell death in the SN (Armentero et al., 2006).
The value of NMDA receptor blockade in humans, particu-
larly for LIDs is clear, although most are limited by side effects.
Once established, LIDs are difficult to treat. Amongst pharma-
cological treatment, amantadine has been proven to be clinically
effective in a small number of clinical trials, while many oth-
ers have only shown promise in animal models. A double-blind,
placebo-controlled clinical study in advanced PD patients has
shown that amantadine reduced dyskinesia severity by approxi-
mately 60%, and improved motor fluctuations in L-Dopa treated
patients (Verhagen Metman et al., 1998). Such findings have
resulted in amantadine becoming the current pharmacological
standard treatment for dyskinesia. However, the long-term effi-
cacy of amantadine has been questioned as its benefits may
decrease over time, though this may be attributed to the rela-
tively short duration of the clinical trial in which the drug was
used (Thomas et al., 2004). A more recent study following PD
subjects over the course of 1 year did not show any significant
loss of benefit suggesting that amantadine may indeed provide
long-term anti-dyskinetic effects (Wolf et al., 2010).
Memantine, another NMDA receptor antagonist that is used
widely to treat Alzheimer’s disease patients, has been sug-
gested to benefit those with Lewy-body-related dementias, with
memantine resulting in greater improvement in cognitive scores
than placebo groups (Emre et al., 2010). Furthermore, meman-
tine resulted in improvement in LIDs and on-off timing, with
the discontinuation of memantine associated with worsening
of dyskinesias and motor fluctuations (Varanese et al., 2010).
Interestingly, a recent clinical trial has demonstrated that treat-
ment with memantine was associated with lower axial motor
symptoms and dyskinesias scores, but did not improve gait
(Moreau et al., 2013).
The widespread expression and critical physiological roles of
NMDA receptors raises the concern that global inhibition of
NMDA receptors may cause severe adverse side effects such as
impaired learning, psychosis, and disruption of motor function
(Paoletti and Neyton, 2007). However, recent evidence suggests
that targeting specific combinations of NMDA receptor subunits
may aid in overcoming this concern. Traxoprodil (CP-101,606),
a selective NR2B antagonist, significantly decreased parkinso-
nian motor symptoms and potentiated L-Dopa responses in
MPTP-treated monkeys and reversed catalepsy in haloperidol-
treated rats (Steece-Collier et al., 2000). Ifenprodil, another
NR2B-selective antagonist, has also been demonstrated to reduce
motor symptoms in MPTP-treated primates (Nash et al., 2000).
Furthermore, these NR2B antagonists improve the efficacy of
L-Dopa and reduce the appearance of LIDs in animal models,
suggesting that a combination approach may be of clinical rel-
evance (Blanchet et al., 1999; Steece-Collier et al., 2000). These
findings in both animal models and clinical trials demonstrate
that NMDA receptor antagonism may provide a significant strat-
egy in the treatment of LIDs. Given their ability to also block
excitotoxicity, there is potential for these drugs to also show
disease-modifying effects.
AMPA receptors
AMPA receptors mediate the vast majority of fast excitatory neu-
rotransmission in the CNS and are important regulators of synap-
tic plasticity (Dingledine et al., 1999; Derkach et al., 2007; Kessels
and Malinow, 2009; Wiltgen et al., 2010; Wright and Vissel,
2012). Given the importance of restoring excitatory balance in
BG circuits, it would be reasonable to suggest that blockade of
AMPA receptors could offer a potential therapeutic target for
treating PD.
Preclinical studies have shown contrasting results, with some
studies suggesting that AMPA receptor antagonists in animal
models do not offer anti-parkinsonian effects when administered
alone (Loschmann et al., 1991, 1992; Wachtel et al., 1992), while
others have found anti-parkinsonian effects both alone and in
combination with dopaminergic therapies. For example, NBQX
has been shown to reverse both reserpine-inducedmuscle rigidity,
but not akinesia, in rats and motor deficits in MPTP-lesioned pri-
mates (Klockgether et al., 1991) and potentiate L-Dopa-induced
reversal of motor deficits in rats and primates with a nigral lesion
(Loschmann et al., 1991, 1992; Wachtel et al., 1992). Studies
also indicate that AMPA receptor antagonists reduce LIDs in
MPTP-lesioned primates, suggesting blockade of AMPA receptors
may reduce motor complications associated with chronic L-Dopa
therapy (Konitsiotis et al., 2000; Silverdale et al., 2005).
To date, only a select number of clinical trials have been
conducted investigating the effect of AMPA receptor antagonists
in PD patients. Perampanel, a non-competitive AMPA receptor
antagonist, whilst showing to be well tolerated and safe, failed to
improve “wearing off” of motor fluctuations (Eggert et al., 2010)
or improve daily “off” time in L-Dopa-treated patients (Lees
et al., 2012) and furthermore failed to perform better against
entacapone, an active comparator (Rascol et al., 2012). Another
AMPA receptor antagonist, talampanel, has been evaluated in a
number of Phase II clinical trials to investigate its safety and
effects on PD symptoms, including LIDs, however, the results
of the trials are not yet available (Clinicaltrials.gov references
NCT00036296, NCT00108667, NCT00004576).
Topiramate, a commonly used anticonvulsant drug, falls into
a separate class of AMPA receptor antagonists as it has been
shown to inhibit both AMPA receptors and the GluK1 subunit
of kainate receptors (Gryder and Rogawski, 2003). Topiramate
has been shown to reduce LIDs in MPTP-lesioned marmosets
without altering the antiparkinsonian action of L-Dopa and
reduce L-Dopa-induced AIMs in 6-OHDA-lesioned rats in a
dose-dependent manner (Silverdale et al., 2005; Kobylecki et al.,
2011). The same animals were also found to have no change in
locomotor score but had a moderately reduced rotarod perfor-
mance at the highest dose. These results suggest that topiramate
may act as an anti-dyskinetic drug in addition to its known
anticonvulsant properties. In addition, topiramate has a synergis-
tic effect with amantadine, another known anti-dyskinetic drug
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(see above), with subthreshold doses of both drugs in combi-
nation attenuating dyskinesias in 6-OHDA-lesioned rats and the
MPTP lesioned marmosets (Kobylecki et al., 2011), suggesting
that combination with low-dose amantadine may provide a better
reduction of dyskinesias with no adverse motor effects.
As topiramate has a good and well-known side-effect pro-
file through its use as an approved anticonvulsant, its use as a
parkinsonian therapy may be able to be expedited to a certain
extent. However, topiramate does have well-recognized behav-
ioral side effects that could be a potential problem in PD patients,
thus some tolerability studies will be required (Aldenkamp et al.,
2000; Kanner et al., 2003). Two Phase II clinical trials were initi-
ated into the anti-dyskinetic effect of topiramate in patients with
LIDs, however, both trials have since been terminated due to poor
recruitment or cessation of funding (Clinicaltrials.gov reference
NCT00794313, NCT00296959). The first published double-blind
placebo-controlled trial investigating the effect of topiramate on
LIDs demonstrated that topiramate in fact increased dyskinesia
severity, contrasting the beneficial effects seen in animal stud-
ies (Kobylecki et al., 2014). A more recent Phase II clinical trial,
which is recruiting patients, will investigate the anti-dyskinetic
ability of topiramate as an adjunct to stable treatment with
amantadine (Clinicaltrials.gov reference NCT01789047).
Metabotropic glutamate receptors
The mGluRs are comprised of eight subunits (mGluR1-mGluR8)
and are subdivided into three groups (I, II, and III) based on
receptor structure and physiological activity (Niswender and
Conn, 2010). Group I mGluRs are expressed throughout the BG
and antagonists of these receptors could be expected to derive
antiparkinsonian effects by reducing excitatory drive in overac-
tive BG nuclei. Indeed, several negative allosteric modulators of
mGluR5 have been shown to have significant effects in animal
models. When administered daily, the mGluR5 negative allosteric
modulator MPEP has been shown to reverse akinesia in bilat-
eral 6-OHDA-lesioned rats (Breysse et al., 2003). Furthermore,
daily administration of MPEP resulted in an induction of ipsilat-
eral rotations in the unilateral 6-OHDA circling model, however,
no effect was seen of MPEP on haloperidol-induced catalepsy
(Breysse et al., 2002). Interestingly, a combined administration of
MPEP with A2A receptor antagonists reversed akinesia induced
by 6-OHDA or reserpine in rodents, suggesting that combin-
ing mGluR5 and A2A receptor blockade may be beneficial in the
symptomatic treatment of PD (Coccurello et al., 2004; Kachroo
et al., 2005).
In addition to a potential symptomatic effect, group I mGluR
antagonism has been suggested to alleviate LIDs. Analysis of
the putamen and pallidum of dyskinetic MPTP-treated primates
showed an increase in mGluR5 binding, which was normalized
when dyskinesias were prevented by NMDA receptor block-
ade (Samadi et al., 2008). Furthermore, the mGluR5 antagonist
MTEP was shown to prevent dyskinesias induced by an acute
challenge of L-Dopa following weeks of L-Dopa priming in 6-
OHDA-lesioned rats (Dekundy et al., 2006; Rylander et al., 2009).
More recently, monkeys rendered parkinsonian with MPTP dis-
played significantly lower dyskinesias when treated with MPEP
+ L-Dopa compared to those treated with L-Dopa alone (Morin
et al., 2013a,b). In contrast, the selectivemGluR1 antagonists such
as EMQMCM or AIDA were shown to be ineffective in a rodent
model of LIDs (Dekundy et al., 2006).
Preclinical studies have also suggested a potential neuropro-
tective role of mGluRs in the early stage of PD. Repeat intranigral
injections of either LY36785, a mGluR1 antagonist or MPEP, a
mGluR5 antagonist, have been demonstrated to attenuate the loss
of nigral neurons and striatal DA levels in 6-OHDA lesioned rats
(Vernon et al., 2005). Furthermore, subchronic intranigral injec-
tions with LY36785 or MPEP slowed dopaminergic cell loss in
rats that were already undergoing nigrostriatal degeneration by
6-OHDA, suggesting a potential neurorescue effect of group I
mGluR antagonism (Vernon et al., 2007). In addition, mGluR5
has been linked to the PD protein alpha-synuclein, with levels
of mGluR5 increasing and co-expressing with alpha-synuclein in
the BG of alpha-synuclein transgenic mice (Price et al., 2010).
Furthermore, these mice displayed an impaired motor perfor-
mance, which was reversed with MPEP, suggesting that mGluR5
may directly interact with alpha-synuclein, contributing to its
activation and role in cell death (Price et al., 2010).
There are a number of clinical trials investigating the effect of
small molecules that target mGluRs on various aspects of PD,
however, a number of these are either in development or have
not published the completed study results. The mGluR5 nega-
tive allosteric modulator ADX48621 (dipraglurant), was revealed
to be safe and tolerable in three Phase I studies of healthy
subjects, allowing for further investigations into its safety, toler-
ability and efficacy in PD patients with moderate to severe LIDs.
In a Phase IIa double-blind, placebo-controlled, multi-center
study (Clinicaltrials.gov reference NCT01336088), dipraglurant
was administered at increasing doses with L-Dopa for 4 weeks.
The results showed no treatment effects on any of the safety
monitoring variables and adverse events were common in both
treatment groups. Furthermore, dipraglurant reduced dyskinesia
severity, with no increase in “off” time and a greater increase in
“on” time without dyskinesia. Interestingly, dipraglurant was as
effective in those in the study that had undergone deep brain stim-
ulation (DBS) as in non-DBS subjects (MichaelJFoxFoundation,
2012).
AFQ056 is another potent, subtype selective inhibitor of
mGluR5 that has been investigated in clinical trials. A Phase II
study investigated multiple oral dose titration of AFQ056 in PD
patients to assess its safety, tolerability and efficacy in reducing
LIDs over a period of 16 days. AFQ056 was shown to signif-
icantly reduce Lang-Fahn Activities of Daily Living Dyskinesia
Scale (LFADLDS) scores on day 16 and significantly reduce aver-
age AIMs on days 12 and 16 (Berg et al., 2011). Based on these
results an open-label Phase II study is currently ongoing to deter-
mine the long-term safety, tolerability and efficacy of AFQ056 in
those patients who were eligible for, participated in, and com-
pleted the previous study (Clinicaltrials.gov reference number
NCT01173731). A recently completed Phase IIb double-blind,
placebo-controlled study investigating the effect of AFQ056 on
LIDs in patients with moderate to severe PD demonstrated sig-
nificant improvements in dyskinesia severity at the highest dose
of AFQ056 administered. However, for all other doses evaluated
the primary endpoint was not met, despite a dose-dependent
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efficacy (Stocchi et al., 2013). An additional Phase II study is cur-
rently underway to investigate the efficacy and safety of modified
release AFQ056, with or without the administration of amanta-
dine, in patients with LIDs (Clinicaltrials.gov reference number
NCT01491529).
SEROTONIN RECEPTOR AGONISTS
In the normal brain, there is a dense serotonergic innervation
of the BG from the raphe nuclei, with the striatum, globus pal-
lidus, and output nuclei receiving high levels of input (Lavoie and
Parent, 1990). Postmortem studies in PD patients have reported
conflicting results with respect to serotonin (5-HT) markers,
however, there is a general consensus that 5-HT is decreased in
the PD brain, suggesting 5-HT may play a potential role in the
disease (Kish, 2003; Scholtissen et al., 2006). Compared to the
changes seen in human tissue, the alteration of the 5-HT system
differs in animal models of PD, with differences seen depending
on toxin, species of animal that is used, and brain region exam-
ined (Erinoff and Snodgrass, 1986; Hara et al., 1987; Zhou et al.,
1991; Rousselet et al., 2003; Boulet et al., 2008).
Regardless, recent evidence strongly suggests that 5-HT neu-
rons may play an important role in L-Dopa-induced DA release
and thus LIDs. It has been suggested that this effect is due to
released DA from spared 5-HT fiber terminals subsequent to their
uptake of repetitive, low doses of L-Dopa. It is thought that, since
these terminals express both aromatic l-amino acid decarboxy-
lase (AADC) and vesicular monoamine transporter 2 (VMAT2),
the 5-HT fiber terminals are able to take up L-Dopa, convert it
into DA, store it within the neuron and then release it in the
DA-depleted brain (Arai et al., 1995; Carta and Bezard, 2011).
The 5-HT terminals therefore facilitate the therapeutic action of
L-Dopa but the raphe-terminals lack auto-regulatory feedback
mechanisms for DA release and can result in excessively enhanced
DA levels in the extracellular space (Carta et al., 2007; Lindgren
et al., 2010). This fluctuation in DA levels then leads to supersen-
sitive responses of striatal neurons and can trigger dyskinesias. A
study conducted by Carta et al. (2007) demonstrated that lesion-
ing 5-HT afferents to the striatum with 5,7-DHT, or inhibiting
neurotransmitter release from 5-HT terminals by administering
5-HT agonists, eradicated established LIDs in animals with both
a partial and complete dopaminergic lesion (Carta et al., 2007).
Furthermore, L-Dopa-naïve, non-dyskinetic rats that had a com-
plete removal of 5-HT afferents failed to develop LIDs when
L-Dopa was subsequently administered.
This finding that 5-HT may regulate L-Dopa-induced DA
release has led to the investigation of molecules acting on 5-HT
receptors as anti-dyskinetic drugs. To date, there are 14 known
distinct subtypes of the 5-HT receptor with many more isoforms.
Nevertheless, the autoreceptors 5-HT1A and 5-HT1B are among
the most studied in PD (Peroutka, 1995). Stimulating 5-HT1A
and 5-HT1B via 8-OH-DPAT and CP-94253, respectively, has
been shown to reduce the activity of the raphe-striatal neurons,
blunt the extracellular DA release in the striatum and attenu-
ate the expression of LIDs in rats lesioned with 6-OHDA (Carta
et al., 2007; Lindgren et al., 2010). These findings have been
replicated in non-human primate models of PD with dyskinetic
monkeys receiving a combination of 5-HT1A and 5-HT1B agonists
displaying an 80% reduction of dyskinesias without a significant
worsening of their parkinsonian scores compared to L-Dopa-only
treated animals (Munoz et al., 2008).
The findings in animal models have resulted in an open-
label, multicenter trial of the 5-HT1A agonist sarizotan’s safety,
tolerability and efficacy in patients with advanced PD com-
plicated by troublesome LIDs. Sarizotan treatment significantly
reduced dyskinesias as measured by home diary, AIMS, and
UPDRS scores. Furthermore, dyskinesia benefits were obtained
without change in total “off” time or in change from baseline
mean UPDRS scores. However, while initially exciting, several
patients experienced worsening parkinsonism with sarizotan or
with increasing doses, due to the fact that sarizotan not only
antagonizes 5-HT1A receptors but also blocks the D4 DA recep-
tor (Olanow et al., 2004). These disappointing results do not
rule out the value of targeting 5-HT receptors, but instead
suggest that sarizotan may not be the ideal therapeutic for
treating LIDs.
These anti-dyskinetic effects were replicated in one double-
blind, placebo-controlled study of sarizotan (Bara-Jimenez et al.,
2005) but were in contrast to a more recent study using a larger
patient population in which no significant changes were found
in dyskinesias measures but an improvement in UPDRS and
“off” time was revealed (Goetz et al., 2007). This lack of effi-
cacy of sariztoan for LIDs could be attributed to the low dose
given during this trial. A number of small clinical trials have
been conducted investigating other 5-HT1A receptor agonists. In
a double-blind, placebo-controlled study, buspirone significantly
lessened the severity of LIDs in 5 out of the 7 patients but proved
ineffective in the remaining 2 who had the mildest dyskinesias
(Bonifati et al., 1994). Another 5-HT1A agonist with 5-HT2 antag-
onism, mirtazapine, was shown in an open label study to be
moderately effective in reducing LIDs both alone and in combi-
nation with amantadine (Meco et al., 2003). In addition a number
of partial 5-HT agonists, including clozapine (Durif et al., 1997,
2004), tandospirone (Kannari et al., 2002) and aripiprazole (Meco
et al., 2009) have also shown some limited success at attenuating
dyskinesias.
Clinical trials of 5-HT receptor agonists as anti-dyskinetic
agents have been somewhat disappointing, though it should be
noted many of these trials consisted of small patient popula-
tions, thus drawing meaningful conclusions from their results is
difficult. Furthermore, these studies have focused on individual
autoreceptor agonism, rather than a dual 5-HT1A and 5-HT1B
agonism approach. This raises the possibility that the failure of
clinical trials to date, at least those targeting 5-HT receptors,
reflects a failure to accurately take the lessons learned in animal
models to the clinical trials, namely that dual 5-HT1A and 5-
HT1B agonism may be required. A recent study demonstrating
the antidyskinetic effect of eltoprazine, a mixed 5-HT1A/5-HT1B
receptor agonist, in both rodents and non-human primates shows
promise that progress is being made in this treatment strategy
(Bezard et al., 2013).
ADRENERGIC RECEPTOR ANTAGONISTS
In addition to the well-documented loss of SN DA cells, it has
been shown that norepinephrine (NE) neurons of the locus
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coeruleus also undergo degeneration in PD and may even pre-
cede the death of DA neurons (Zarow et al., 2003; Fornai et al.,
2007; Mcmillan et al., 2011). These adrenergic neurons originat-
ing from the LC appear to play a protective role by establishing the
extent of nigral degeneration induced by both neurotoxic dam-
age and by pathological events underlying PD (Mavridis et al.,
1991; Fornai et al., 2007; Rommelfanger et al., 2007). It is there-
fore thought that activation of adrenergic pathways through the
blockade of adrenergic autoreceptors, in particular the α2 recep-
tor, should oppose the nigrostriatal dopaminergic degeneration
and the subsequent motor deficits in PD.
It has been suggested that activation of α2 adrenergic recep-
tors can facilitate movements produced by the activation of the
direct pathway of the BG, thus highlighting enhanced α2 recep-
tor stimulation as a potential mechanism underlying LIDs (Hill
and Brotchie, 1999). Indeed, the α2 adrenergic receptor antag-
onist yohimbine significantly reduced L-Dopa-induced hyper-
kinesia in 6-OHDA-lesioned rats. These effects did not reflect
non-specific reductions in locomotion, as the rats did not dis-
play significantly reduced levels of spontaneous locomotion, thus
indicating a specific effect on L-Dopa-induced effects (Henry
et al., 1998). Furthermore, rats receiving 6-OHDA without con-
comitant administration of desipramine, thus lesioning both the
DA and NE systems, demonstrated markedly reduced L-Dopa-
induced rotations (Barnum et al., 2012). In addition, the α2
adrenergic receptor antagonist idazoxan was effective in alleviat-
ing the expression of AIMs in rats lesioned with 6-OHDA alone
(Barnum et al., 2012) and reducing haloperidol-induced catalepsy
(Invernizzi et al., 2003). These results were confirmed in stud-
ies of MPTP-lesioned non-human primates with α2 adrenergic
receptor antagonists significantly reducing LIDs without compro-
mising the anti-parkinsonian action of L-Dopa (Gomez-Mancilla
and Bedard, 1993; Henry et al., 1999; Fox et al., 2001; Savola
et al., 2003). Fipamezole, a more recently developed α2 adren-
ergic receptor antagonist, has also been shown to extend both
the duration and quality of L-Dopa action with total “on” time
increased by up 75% and “on time without disabling dyskinesia”
increased by up to 98% in MPTP-lesioned macaques (Johnston
et al., 2010).
To our knowledge, only idazoxan and fipamezole have subse-
quently progressed to clinical trial investigations. In a random-
ized, placebo-controlled pilot study, the effects of single oral doses
of idazoxan on motor disability and LIDs following an acute oral
challenge of L-Dopa was assessed in 18 patients with PD, with ida-
zoxan able to improve the severity of LIDs without a concomitant
deterioration of the antiparkinsonian effect of L-Dopa (Rascol
et al., 2001). Meanwhile a recent 28 day dose-escalating effect of
fipamezole was investigated in a Phase II double-blind, random-
ized, placebo-controlled study in PD patients experiencing LIDs.
The total study population showed no statistically significant
primary endpoint difference between fipamezole and placebo,
however, this may be attributed to the non-homogenous US and
Indian study populations. Therefore analysis of a subgroup of US
subjects was conducted with fipamezole reducing LIDs in a dose-
dependent manner and inducing mild, transient blood pressure
elevation, which was considered as an acceptable profile of adverse
events (Lewitt et al., 2012). There have been 3 other clinical trials
investigating fipamezole that have been completed, however, no
study results have been published (Clinicaltrials.gov references
NCT01149811, NCT01140841, NCT00040209).
CALCIUM CHANNEL BLOCKERS
One of the most popular held theories of aging is that it is a direct
consequence of accumulated mitochondrial DNA damage pro-
duced by reactive oxygen species (ROS) and free radicals gener-
ated in the course of oxidative phosphorylation (Harman, 1972).
It could be hypothesized that the reliance of DA neurons on the
metabolically expensive action of sequestering calcium (Ca2+),
results in these neurons aging more rapidly than other types of
neurons. Indeed, histological estimates of normal aging-related
cell death suggest this may be the case (Stark and Pakkenberg,
2004).
It has been suggested that the specific physiology of nigral DA
neurons may provide some answers as to why there is preferen-
tial loss of these cells in PD. Unlike most other neurons in the
CNS, the DA neurons of the SN generate rhythmic action poten-
tials in the absence of synaptic input. Furthermore, most other
neurons use channels that allow sodium (Na+) ions across the
membrane to mediate pacemaking whereas nigral DA neurons
rely upon L-type Ca2+ channels (Bonci et al., 1998). These L-
type channels have a pore-forming Cav1.3 subunit rather than
the cardiac Cav1.2 subunit (Striessnig et al., 2006), however, as
Ca2+ is central to a wide variety of cellular processes this reliance
on Cav1.3 Ca2+ channels may be problematic. In addition, in
nigral DA neurons the Ca2+ channels are open much of the time,
thus the magnitude of Ca2+ influx is greater and subsequently
increases the burden and vulnerability of the cell to failed Ca2+
homeostasis leading to cell death (Wilson and Callaway, 2000).
Interestingly, the reliance of nigral DA neurons upon Ca2+
channels to drive pacemaking is developmentally regulated.
Young neurons generate their activity autonomously via Na+
channels, with this mechanism retained in adult neurons but in a
latent capacity (Chan et al., 2010). Furthermore, sustained block
of Cav1.3 Ca2+ channel-induced pacemaking “rejuvenates” this
juvenile mechanism and results in DA neurons spiking at normal
rates and mice displaying no obvious motor, learning or cognitive
deficits (Chan et al., 2007). If PD is a consequence of the acceler-
ated aging of neurons that rely heavily upon Ca2+ channels, then
reducing this dependence and forcing back to an L-type chan-
nel independent mechanism should slow PD progression and/or
delay clinical manifestations of PD.
Ca2+ channel blockers have been used for decades to treat
hypertension. Post-hoc analysis of patients treated with one of the
hypertensive drug classes known as dihydropyridines, revealed
a lower incidence of PD (Rodnitzky, 1999). This positive effect
resulted in numerous investigations of this class of drugs, in par-
ticular isradipine, in animal models of PD. In one study, mice
systemically administered isradipine with slow-release, subcuta-
neous pellets showed a strong protection of nigral neurons against
6-OHDA-induced cell death (Chan et al., 2010). This neuro-
protection was confirmed using an osmotic pump delivery sys-
tem, with isradipine providing a dose-dependent sparing of DA
fibers in the striatum and nigral DA neurons (Ilijic et al., 2011).
Isradipine was also shown to protect against MPTP-induced
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toxicity in mice with a reduction of loss of dopaminergic SN
cells by nearly half whilst preventing the development of motor
deficits (Chan et al., 2007). Interestingly, subcutaneous isradip-
ine administration in rats lesioned with 6-OHDA attenuated L-
Dopa-induced rotational behavior and AIMs in a dose-dependent
manner, suggesting that blocking L-type Ca2+ channels may also
provide a symptomatic benefit in addition to its neuroprotective
role (Schuster et al., 2009).
While there is a significant benefit of isradipine in animal
models of PD, a potential therapeutic caveat of using 1,4-
dihydropyridines (DHPs), a group of drugs of which isradip-
ine belongs to, is that they are not selective. Among the
DHPs, isradipine has the highest affinity for Cav1.3 chan-
nels, however, it is still Cav1.2 selective (Lipscombe et al.,
2004). A recent study aimed to overcome this issue by per-
forming high-throughput screening of chemical libraries with
subsequent modification, identifying 1-(3-chlorophenethyl)-3-
cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione as a potent and
highly selective Cav1.3 L-type Ca2+ channel antagonist (Kang
et al., 2012). It is hopeful that this study will open the field
to further development of selective antagonists and subsequent
preclinical and clinical evaluation.
There is currently very little clinical evidence of the use of
Ca2+ channel blockers in patients with PD. One clinical trial,
which followed on from an earlier safety and tolerability study,
showed that isradipine was reasonably tolerated. Furthermore the
main side effect of leg oedema was reversed with dose reduction
(Simuni et al., 2010; Rees et al., 2011). This was confirmed in a
more recent study demonstrating a dose-dependent tolerability
of isradipine, however, no differences in reduction of symptoms
were found (Parkinson Study Group, 2013). However, the authors
note that this may be due to their design not being powered for
efficacy or futility analysis. However, the identification of a toler-
able dose supports the use of isradipine for future efficacy trials.
Importantly a large Phase III clinical trial of isradipine is now in
development (Michael J Fox Foundation, 2014).
GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AGONIST
The apparent link between diabetes and Parkinson’s risk has
gained significant attention in recent times and it is increas-
ingly suggested, including by us, that anti-diabetes drugs may
offer benefit for neurological diseases, independent of their anti-
diabetic actions (Clark et al., 2012; Clark and Vissel, 2013). The
insulin-tropic hormone glucagon-like peptide-1 (GLP-1) is an
endogenous peptide that has been developed to treat diabetes and
that controls plasma glucose levels. Recently, GLP-1 and analogs
with extended action have emerged as a highly novel target to treat
PD.
Exendin-4, a long-acting analog of GLP-1, was shown to have
neurotrophic and neuroprotective properties, similar to other
neurotrophic factors, in cultured PC12 cells subjected to exci-
totoxic stress (Perry et al., 2002a,b), suggesting that stimulation
of GLP-1 receptors may be therapeutically beneficial in neurode-
generative disorders such as PD. We have extensively reviewed
the mechanisms by which GLP-1 agonists may show benefit for
neurodegenerative disease (Clark et al., 2012; Clark and Vissel,
2013).
Exendin-4 was found to protect ventral dopaminergic cells
in culture that were exposed to 6-OHDA, an effect that was
replicated in SH-SY5Y cells, which can be differentiated into
neurons with a dopaminergic phenotype (Li et al., 2009). This
same study revealed that exendin-4 treatment protected against
MPTP-induced toxicity, with mice receiving exendin-4 having
significantly higher numbers of dopaminergic neurons, pre-
served DA levels and improved scores in multiple motor testing
paradigms.
Exendin-4 may also be able to arrest and possibly reverse
nigrostriatal lesions once the neurodegeneration has already
begun. Mice receiving exendin-4 1 week following 6-OHDA-
lesioning displayed significantly lower apomorphine-induced cir-
cling, higher striatal DA concentrations and nigral tyrosine
hydroxylase (TH) staining, indicating a potential neurorescue
effect (Harkavyi et al., 2008). Interestingly, these protective effects
were also found when mice received SN lesions of lipopolysac-
charide (LPS) instead of 6-OHDA, suggesting that exendin-4 may
also have anti-inflammatory effects.
Clinically, exendin-4 has been used as a treatment for type
2 diabetes since 2005, with very little investigation of its use
in PD. However, a recent Phase II clinical trial aimed to show
proof of concept of exendin-4 on the progress of 45 patients with
moderate PD. In the single-blind trial, patients received subcuta-
neous injection of exendin-4 for 12months and showed improved
motor and cognitive function that persisted for 2 months after
treatment had stopped (Aviles-Olmos et al., 2013). A potential
caveat to this study was the lack of placebo control. However,
the authors note this was due to the complex drug device and
the cost of manufacture of a matched placebo. Nevertheless, this
cost-efficient proof-of-concept study may open doors for future
rigorous double-blind, placebo-controlled trials.
IRON CHELATORS
A healthy SN has a higher concentration of iron than the liver,
which is the main store of iron in the body (Mastroberardino
et al., 2009). Iron in neuronal cells is usually bound to ferritin,
neuromelanin, or stored in the lysosome and iron homeostasis
is crucial for multiple brain functions and is tightly regulated by
a number of mechanisms (Li et al., 2011). It has become appar-
ent that iron mismanagement within the brain may contribute
to a variety of neurological disorders, including PD. Iron accu-
mulation in the SN of PD patients was first described in 1924,
interestingly before the identification of DA deficiency, and has
been suggested as a contributing factor for DA neuron degener-
ation (Berg and Hochstrasser, 2006). It has been suggested that
an increase in iron results in oxidative stress within the SN and
exacerbates the neurotoxicity of other alleged pathogens, such
as neuromelanin and endogenous DA, and consequently lead to
preferential DA neuron degeneration (Cozzi et al., 2010).
As 6-OHDA is thought to induce nigrostriatal degeneration via
metal-catalyzed free radical formation, the effect of iron chela-
tors was first investigated in this model. Intracerebroventricular
administration of desferrioxamine (also known as desferoxamine,
DFO, or desferal) prior to 6-OHDA has been demonstrated to sig-
nificantly protect against reduction in striatal DA content and a
normalization of DA release in rats. Desferrioxamine-pretreated
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rats also exhibited normal behavioral responses in contrast to
animals treated with 6-OHDA alone, which demonstrated sig-
nificantly impaired rearing and spontaneous movements in a
novel environment (Ben-Shachar et al., 1991, 1992; Youdim et al.,
2004). Furthermore, desferrioxamine alone did not affect stri-
atal TH activity or DA metabolism. These results led to the
development of the novel brain-permeable iron chelator, VK-28,
with pretreatment able to completely protect against 6-OHDA-
induced depletion of DA and its metabolites in rats (Shachar
et al., 2004). This neuroprotective effect has been replicated in
the MPTP model, with the iron chelators desferrioxamine, clio-
quinol, and M30 significantly increasing DA levels and nigral
dopamine neuron numbers followingMPTP administration (Lan
and Jiang, 1997; Kaur et al., 2003; Gal et al., 2005; Youdim,
2012).
Iron chelators are already used in the clinic as treatment strate-
gies for various conditions. Desferrioxamine has been the most
widely used iron chelator over the last three decades, however, its
inability to cross the blood brain barrier in concentrations that are
therapeutically efficacious has restricted its use in neurodegenera-
tive disorders. The chelators deferiprone and clioquinal are able to
be administered orally and thus have a great advantage over des-
ferrioxamine. A number of Phase II clinical trials investigating the
safety and efficacy of deferiprone in patients with PD, with sub-
jects assessed via UPDRS scores and, when possible, by magnetic
resonance imaging are currently underway (Clinicaltrials.gov ref-
erences NCT01539837, NCT00907283). A recently completed
trial in early PD patients demonstrated a significant reduc-
tion in accumulated iron levels in the SN and a corresponding
improvement in motor symptoms in patients receiving immedi-
ate treatment of deferiprone, while those assigned to a delayed
start paradigm experienced worsening of symptoms initially, fol-
lowed by improvement in motor function upon treatment with
deferiprone (Devos et al., 2014). Further multi-center trials will
be required to consolidate these findings and investigate the
mechanism of action of deferiprone in the clinical setting.
ANTI-INFLAMMATORIES
The term “neuro-inflammation” is currently ill defined. However,
for now, as is apparent from the literature, inflammation in the
brain will generally continue to be defined by the presence of reac-
tive astrocytes and amoeboid microglia, together with expression
of inflammatory cytokines. It is widely accepted that such inflam-
mation occurs in the PD brain, although it is currently unknown
as to what initiates the inflammatory response and whether it
is part of an attempt, at least initially, to repair the brain or a
consequence of nigrostriatal degeneration. We, and others have
suggested that the issue may not be inflammation in the CNS per
se, but may be, more importantly, an interference with normal
glial function at the synapse (Abdipranoto-Cowley et al., 2009;
Clark et al., 2010; Morris et al., 2013). If true, then the therapeu-
tic target for PD and neurodegenerative disease more generally
will not ultimately be inflammation, but rather will be focused on
restoring synapse function, in part through restoring the normal
functions of glia at the synapse.
The first evidence for a role of inflammation in PD
resulted from a study conducted on post mortem brains, which
demonstrated reactive microglia in the SN in patients with PD
(Mcgeer et al., 1988). Reactive astrocytes are generally thought to
be absent or described as mild or moderate in PD brains (Mirza
et al., 2000). Ever since, there have been a large number of studies
that have supported the role of activated microglia and increased
levels of inflammatory mediators such as cytokines, chemokines
and ROS in the pathology of PD (Mogi et al., 1994; Banati et al.,
1998; Knott et al., 2000; Reale et al., 2009). Whilst it has been
suggested that mild activation of microglia has beneficial effects,
chronic activation, as is evident in PD, is thought to contribute
to the death of otherwise viable cells (Gao and Hong, 2008).
Furthermore, there is a wealth of evidence from animal models
regarding the role of inflammation in the pathogenesis of PD,
with inflammatory markers identified in 6-OHDA (Marinova-
Mutafchieva et al., 2009; Harms et al., 2010; Wachter et al., 2011),
MPTP (Grunblatt et al., 2001; Mcgeer et al., 2003; Yasuda et al.,
2008; Barcia et al., 2011), paraquat (Cicchetti et al., 2005; Mitra
et al., 2011) and rotenone models of PD (Sherer et al., 2003;
Phinney et al., 2006).
Given the observation that inflammation is seen in the
PD brain, there has been interest in the potential of anti-
inflammatory drugs for treating PD. Non-steroidal anti-
inflammatory drugs (NSAIDs) are the main drugs used to
reduce the effects of inflammation. NSAIDs work by inhibiting
cyclooxygenase (COX), an enzyme that catalyzes the formation of
prostaglandins, as well as having an inhibitory effect in the syn-
thesis of nitric oxide radical (Asanuma and Miyazaki, 2007). A
number of anti-inflammatories have been investigated in animal
models of PD including aspirin and its metabolite salicyclic acid,
as well as COX-1 and COX-2 inhibitors.
Both aspirin and salicyclic acid have been shown to be neu-
roprotective against MPTP-induced striatal DA depletion and
dopaminergic nigral death inmice through effective scavenging of
hydroxyl radicals (Aubin et al., 1998; Ferger et al., 1999). However,
subsequent studies indicated that COX-1 and COX-2 enzymes
may play a bigger role. This was confirmed in studies investi-
gating the COX inhibitor meloxicam, with high doses showing
almost complete protection against MPTP-induced toxicity with
decreased striatal DA depletion, attenuation of reduction of TH-
immunoreactive cells in the SN and MPTP-induced decrease in
locomotor activity (Teismann and Ferger, 2001). Another COX
inhibitor, indomethacin, was also shown to protect dopaminer-
gic neurons within the SN in mice following MPTP and also
decreased microglial activation and lymphocytic infiltration in
the damaged areas, however, it appeared to be toxic at high
doses (Kurkowska-Jastrzebska et al., 2002). COX inhibitors have
also shown to be protective against the toxic effects of 6-OHDA.
Celocoxib, a COX-2 inhibitor, when administered to rats lesioned
with 6-OHDA protected against intrastriatal degeneration and
resulted in decreased microglial activation in the striatum and
ventral midbrain (Sanchez-Pernaute et al., 2004).
Despite the evidence of inflammation in postmortem brains
and various animal models, the use of NSAIDs has not been for-
mally tested in clinical trials of PD. However, epidemiological
studies suggest that the use of non-aspirin NSAIDs is associated
with a 15% reduction in risk of PD, a 29% reduction with reg-
ular use and a 21% reduction with long-term use, suggestive of
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a dose-response relationship (Gagne and Power, 2010). However,
many questions remain before their use as a PD therapy, such as
the most appropriate patient population, drug type, dose, and
length of administration. Furthermore, the use of NSAIDs has
been associated with adverse effects such as gastrointestinal side
effects, which may hamper their use at sufficient doses in the
clinic.
The side effects of NSAIDs limit the dose at which they can be
used in the clinic. Consequently, it is possible that the limited evi-
dence supporting the efficacy of anti-inflammatories may result
from a problem as simple as a lack of sufficient dosing. Indeed
high doses of anti-inflammatories have been used in animal mod-
els to suppress inflammation (Abdipranoto-Cowley et al., 2009;
Mertens et al., 2013), doses that would cause substantial side
effects with chronic use in humans.
The anti-inflammatory properties of minocycline provide an
alternative to the use of NSAIDs in the clinic. As one of the
treatment arms in the Phase II randomized, double-blind NET-
PD clinical trial, which also investigated creatine, twice daily
administration of minocycline was examined for its potential to
alter the course of early PD relative to a predetermined futility
threshold of 30% reduction in UPDRS progression. The results
demonstrated that minocycline could not be rejected as futile
for future studies when examined against this predetermined
threshold (The Ninds Net-Pd Investigators, 2006). An additional
6-month follow up study demonstrated that by 18 months from
starting minocycline, 62% of patients required further symp-
tomatic treatment. However, minocycline did not adversely affect
this symptomatic treatment or increase adverse events (TheNinds
Net-Pd Investigators, 2008).
There continues to be an ever-increasing literature on the role
of inflammation in PD (Amor et al., 2010; Hirsch et al., 2012;
Phani et al., 2012), however, understanding of neuroinflamma-
tion is still in its earliest stages and this may be constraining
advances in this area. More generally, a great deal remains to
be learnt regarding the role of glial cells and the mechanisms
that regulate their function in the normal and diseased brain
(Morris et al., 2013). It is conceivable that the issue is not classical
inflammation at all, but rather a failure of normal glial function
occurring in the diseased brain. Thus, general anti-inflammatory
approaches may not show the specific effects needed for disease-
modification andmore specific targeting of signalingmechanisms
that regulate glial function and responses will ultimately be
required.
GENE THERAPY
A great advance in the field of PD therapeutics and an alterna-
tive to traditional pharmacological approaches includes the viral
vector-mediated targeted delivery of therapeutic genes such as
aromatic amino acid decarboxylase (AADC) and glutamic acid-
decarboxylase (GAD). The advantage of gene therapy lies in the
potential to deliver therapies in a tightly controlled manner to
specific brain regions, limiting the chance of off-target effects. The
disadvantages continue to include the inability to tightly regulate
the amount delivered and the fact that the treatments are largely
irreversible. For these reasons, while promising, gene therapy has
been regarded as experimental.
Aromatic L-amino acid decarboxylase (AADC)
Aromatic L-amino acid decarboxylase (AADC) is an enzyme
that converts L-Dopa to DA, offering an attractive target to
endogenously stimulate production of DA in surviving neurons.
Using the adeno-associated virus (AAV) as a delivery method,
AADC has been shown to decarboxylate endogenous levels of L-
Dopa more efficiently when injected into animal models of PD.
In rats lesioned with 6-OHDA, animals that received AAV-AADC
demonstrated rotational scores that were strongly correlated with
AADC activity in the lesioned striatum and restoration of DA
production to 50% of normal levels by 12 weeks after receiv-
ing the gene therapy (Sanchez-Pernaute et al., 2001). In addition,
the gene transfer-induced increase in striatal decarboxylation of
peripherally administered L-Dopa was shown to remain undi-
minished over a 6 month period and expression of the transgene
was detected for at least 1 year (Leff et al., 1999). Furthermore,
simultaneous infection of 6-OHDA-lesioned rats with AAV-TH
and AAV-AADC resulted in more effective DA production and
a greater behavioral recovery than was seen in rats receiving
AAV-TH alone (Fan et al., 1998).
In two Phase I clinical trials, 6-month evaluation of AAV-
AADC into the striatum improved off-medication motor func-
tion of almost 50% of UPDRS scores and increased AADC activity
in the striatum, however, three out of the 10 subjects in one
of the studies suffered hemorrhage along the trajectory of the
injecting catheter (Christine et al., 2009; Muramatsu et al., 2010).
Clearly such risks are unacceptable and will need to be addressed.
Nevertheless, a long-term follow up study revealed that AADC
gene expression was maintained at least 4 years after adminis-
tration, indicating transgene stability (Mittermeyer et al., 2014)
though further trials will be needed to determine if a higher
vector dose is able to induce a similar stable effect on motor
symptoms.
A recently completed Phase I/II clinical trial investigating
ProSavin, a lentiviral vector encoding AADC, along with tyro-
sine hydroxylase and cyclohydrolase 1, demonstrated a signifi-
cant improvement in UPDRS scores up to 12 months following
ProSavin administration (Palfi et al., 2014). While these posi-
tive outcomes describe the first use of a lentiviral-based vector in
a neurodegenerative disease, further optimization of mode and
dose of delivery will be required before proceeding to further
clinical trials.
Glutamic acid decarboxylase (GAD)
As noted above it is thought that nigrostriatal degeneration leads
to excessive inhibitory output from the GPi and SNr. This is due
to disinhibition of the STN, which drives the GPi and SNr via
the release of glutamate, suggesting that a gene transfer strategy
that enhances GABA transmission in the STN and its termi-
nal regions via GAD may be therapeutically beneficial. A study
conducted by Luo et al. (2002) showed that GAD65 into the
STN mediated an increase in survival of midbrain dopaminergic
neurons. Furthermore, rotation rates in GAD65-transduced 6-
OHDA-lesioned rats were decreased by 65%, a result confirmed in
subsequent studies (Luo et al., 2002; Lee et al., 2005). In addition,
administration of AAV-GAD65 into the STN revealed significant
improvement in bradykinesia, gross motor skills, and tremor in
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macaques rendered hemiparkinsonian by MPTP (Emborg et al.,
2007).
Following these promising animal studies, the administration
of AAV-GAD was examined in PD patients. An open-label study
in 12 patients with advanced PD followed over a 12-month period
after unilateral injections of AAV-GAD into the STN, demon-
strated a significant improvement in UPDRS scores, expressed
predominantly on the side of the body contralateral to the surgery
and were seen after 3 months and persisted up to 12 months after
gene therapy (Kaplitt et al., 2007). A phase II sham-surgery con-
trolled study of bilateral infusions of AAV-GAD into the STN
of progressive L-Dopa responsive PD patients showed signifi-
cant reductions in off-medication UPDRS motor scores. With no
serious safety concerns reported so far (Lewitt et al., 2011), this
remains as a promising direction of research.
Gene therapy for delivery of neurotrophic factors
Viral mediated delivery of the neurotrophic factors glial derived
neurotrophic factor (GDNF) and neurturin (NTN) to specific
CNS regions have also been extensively explored as potential ther-
apeutics for PD. We will elaborate on these efforts as part of a
more general discussion about neurotrophic factors below.
NEUROTROPHIC FACTORS
While their mechanism of neuroprotective action is poorly under-
stood, there has been a long held interest in the potential benefits
of neurotrophic factors for treating PD. Several studies have pro-
vided evidence that neurotrophic factors can provide beneficial
effects on dopaminergic neurons (Collier and Sortwell, 1999;
Rosenblad et al., 1999). Consequently, they have been extensively
investigated as described below.
Glial derived neurotrophic factor
GDNF is an important survival factor for midbrain dopaminer-
gic neurons and stimulates the growth of process from immature
neurons (Lin et al., 1993) providing an attractive therapeutic
target for halting PD degeneration. Both the density of TH
immunoreactivity and DA levels were significantly rescued in
mice in which GDNF was injected into the SN before MPTP
lesioning or into the striatum 7 and 16 days after lesioning,
indicating both a protective and restorative effect on dopamin-
ergic neurons (Tomac et al., 1995). Administration of GDNF to
the region just above the SN 1 week following 6-OHDA lesion
resulted in a partial but substantial protection of nigral neu-
rons, but with the remaining neurons appearing significantly
atrophied, indicating that proximity of GDNF administration to
the site of lesion is important for preserving neural function
(Sauer et al., 1995). Indeed, the site of GDNF administration
has been shown to have differential effects in rodent models of
PD. In rats lesioned with 6-OHDA, prior injection of GDNF into
the striatum resulted in preservation of striatal terminals, nigral
cell bodies and preservation of motor function while intranigral
injections resulted in protection of nigral cell bodies but no sub-
sequent preservation of DA axons or behavioral outcomes (Kirik
et al., 2000a).
The beneficial effects of GDNF have also been demonstrated
in non-human primate models of PD. Intracerebroventricular
GDNF delivered monthly in MPTP-treated monkeys resulted
in decreased parkinsonism in a dose responsive manner, atten-
uated LIDs (Miyoshi et al., 1997; Zhang et al., 1997), and
is correlated with increased levels of the DA metabolites 3,4-
Dihyroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA) (Gerhardt et al., 1999).
Based on these results, a randomized double-blind clinical
trial was initiated using intracebroventricular GDNF infusion.
However, the results were disappointing, with no clinical
improvement, an absence of neuroprotection and GDNF dif-
fusion in the brain parenchyma (Kordower et al., 1999).
Furthermore, a Phase II double-blind, placebo-controlled study
conducted by AMGEN of continuous infusion of GDNF into the
putamen, while showing the therapy to be well-tolerated did not
meet the primary endpoint at 6 months, with no improvement in
UPDRS scores. In addition, AMGEN suddenly halted the study as
a result of identification of cerebellar lesions in preclinical non-
human primate studies, prompting fears for the long-term safety
of patients in the trial (Amgen, 2005). Continuous infusion using
a minipump system was then trialed, however, these studies pro-
vided conflicting results, strengthening gene therapy as a potential
alternative delivery method (Nutt et al., 2003; Slevin et al., 2007).
Several studies have been conducted in animal models of PD
using adenovirus, lentivirus and AAV-based vectors to express
GDNF in the striatum or SN. One study, using a lentiviral vector,
resulted in an eightfold increase in TH immunoreactive neu-
rons in aged monkeys and a sevenfold increase in those rendered
parkinsonian with MPTP (Palfi et al., 2002). However, the most
promising studies are those utilizing the AAV vector, with GDNF
expression achieved for up to 6 months in rats with a single injec-
tion of AAV-GDNF. Furthermore, AAV-GDNF administered to
both the nigra and striatum was revealed to be capable of pro-
viding complete protection of nigral neurons following 6-OHDA.
However, as occurred with infused GDNF, the site of GDNF deliv-
ery was crucial to functional outcome with only AAV-GDNF
administered to the striatum providing functional recovery (Kirik
et al., 2000b). Another study, using an AAV vector revealed that a
delayed delivery of GDNF in 6-OHDA lesioned rats resulted in
significantly higher density of TH immunoreactive fibers in the
striatum and neurons in the SN as well as higher levels of DA
and its metabolites, resulting in a significant behavioral recovery
(Wang et al., 2002).
These beneficial effects have been replicated in non-human
primate models of PD with AAV-GDNF shown to protect nigral
neurons, provide a partial protection of DA fibers in the striatum,
and bring about a clinical improvement in monkeys lesioned with
6-OHDA and MPTP (Eslamboli et al., 2003; Eberling et al., 2009;
Johnston et al., 2009). Despite the successful outcomes in animal
models of PD, clinical trials assessing the efficacy of AAV-GDNF
treatment have yet to be conducted, with only one Phase I trial
utilizing convection enhanced delivery of AAV-GDNF currently
recruiting participants (ClinicalTrials.gov NCT01621581).
Neurturin
Another neurotrophic factor that is a close homolog of GDNF,
called neurturin (NTN), emerged as a potential therapeutic tar-
get. NTN is 40% identical to GDNF and while it is known to
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support the survival of a variety of peripheral neurons, the com-
plete extent of its function is yet to be determined (Kotzbauer
et al., 1996). Much like GDNF, the injection of recombinant NTN
has demonstrated variable results in animal models of PD. In one
study, the delivery of NTN into the striatum after 6-OHDA lesion-
ing in rats resulted in a 72% protection of nigral DA neurons but
failed to rescue DA levels in the striatum (Rosenblad et al., 1999).
In contrast, a study by Oiwa et al. (2002) demonstrated that NTN
administered 12 weeks following 6-OHDA failed to protect nigral
neurons but increased striatal DA fibers (Oiwa et al., 2002).
Again, the use of viral vector-mediated delivery has provided
the most efficacious method for the therapeutic administration
of NTN. A recombinant AAV2-based vector encoding for human
NTN, known as CERE-120, has been developed by Ceregene Inc.
When administered into the striatum in rats, NTN expression has
been shown to be rapid, increasing significantly up to 4 weeks, sta-
ble for at least 1 year (Gasmi et al., 2007b) and provides protection
of nigral neurons against 6-OHDA-induced toxicity in a dose-
dependent manner (Gasmi et al., 2007a). In aged monkeys receiv-
ing unilateral striatal injection of AAV2-NTN, there was robust
expression of NTN and a significant increase in TH positive fibers
in the striatum and an increase in the number of nigral TH pos-
itive cells 8 months post-administration (Herzog et al., 2007).
In MPTP-treated hemiparkinsonian monkeys, administration of
AAV2-NTN after lesioning produced long-lasting improvement
in motor function within 1–3 months, persisting up to 10 months
while also providing protection of nigral neurons and striatal DA
fibers (Kordower et al., 2006).
Based on these positive results, an open label Phase I study
was conducted to investigate the safety and tolerability of bilateral
putamen injections of CERE-120 in 12 patients with advanced
PD, resulting in no significant adverse effects, a significant
decrease in UPDRS “off” scores, increase in “on” time without
dyskinesias, and a reduction in “total off” time (Marks et al.,
2008). Based on these findings a double-blind, sham surgery
controlled Phase II trial was conducted in PD patients, though
no changes in UPDRS “off” scores were found (Marks et al.,
2010). However, post-mortem analysis of 2 subjects revealed
deficits in retrograde transport of CERE-120 from the putamen
to the SN (Bartus et al., 2011). This result led to a large Phase
I/IIb trial investigating the effects of CERE-120 when admin-
istered both intraputaminally and intranigrally, with Phase I
stage complete and CERE-120 being received without complica-
tions (Bartus et al., 2013). Data from the Phase IIb study was
recently announced by Ceregene, with no significant differences
between treatment groups in the primary endpoint as measured
by UPDRS scores. However, according to the company, a signifi-
cant difference was found in patient diary “off” scores, one of the
key secondary endpoints (Ceregene, 2013). While the results of
this trial are disappointing, they provide further evidence for the
safety of CERE-120 and the use of gene therapy a viable strategy
for the delivery of neurotrophic factors.
THE NEXT STAGES OF THERAPEUTIC DEVELOPMENT
It is clear that the therapeutics discussed in this review have
emerged out of an increasingly well-grounded knowledge of the
circuits underlying BG function and the role of neurotransmitters
and neural regulation in these circuits (Figure 1). Consequently,
while L-Dopa remains the mainstay of treatment, the major
advances are coming from directing treatments to modify other
aspects of BG circuit function. While many of these non-
dopaminergic treatments may not erase the need for DA replace-
ment strategies, they may support the use of these therapies
through the reduction in L-Dopa dose, improvement of motor
symptoms, and/or reducing LIDs.
We have only focused on the new wave of treatments that
have shown promise in animal models and that have also gone to
human clinical trials, however, efforts to identify ever more viable
therapeutic targets continues. Notable developments in animal
models in this area include histamine H3 antagonists which, in
addition to their non-motor effects, are able to improve L-Dopa-
induced motor effects (Nowak et al., 2008); dopamine uptake
inhibitors, which potentiate the efficacy of L-Dopa (Huot et al.,
2014); and conserved dopamine neurotrophic factor (CDNF),
which has demonstrated neuroprotective properties and rescue
of motor deficits (Ren et al., 2013). This, together with efforts
directed to address the basic mechanisms and causes of PD, our
increased understanding of genetics, and recent extensive efforts
to develop new biomarkers that should in turn improve clinical
trials, provides a great basis for optimism.
The next stage, in particular the development of neuropro-
tective drugs, will require advances in basic science, specifically,
an understanding of the basic biology of PD including (1) the
increasingly accepted role of non-neuronal cells in neurodegener-
ative diseases, (2) the underlying disease mechanisms (3) whether
genetic mutations fit into multiple separate pathways that define
different forms of the disease, or whether they fit in a single
pathway that will ultimately elucidate the cause of PD and con-
sequently, (4) consideration of PD as multifactorial and perhaps
as several different diseases that manifest similarly, (5) advances
in clinical trial design and interpretation, possibly assisted by
biomarker measurements and (6) identification of early events
and understanding the validity of Braak staging and its implica-
tions. We consider only some of these points briefly below.
THE ROLE OF GENETICS
Considerable advances have been made in the identification
of genes associated with PD (Klein and Westenberger, 2012;
Singleton et al., 2013), though further research remains to be con-
ducted to further understand the relationship between genetic
factors, PD onset, and clinical manifestation. These genetic stud-
ies have provided a basis for research into the molecular pathways
underlying PD. However, it remains an issue that genetic pene-
trance varies, suggesting that mutant genes alone do not necessar-
ily cause PD, indeed mutations account for approximately 30% of
familial and 3–5% of sporadic PD cases (Klein andWestenberger,
2012). Furthermore, it is unclear if all mutations associated with
PD risk cause a similar phenotype. Thus, it remains uncertain as
to how applicable outcomes of molecular and biochemical stud-
ies of specific genes will be relevant to the PD populations more
generally.
An important outcome of genetic studies is that they offer a
potential approach to model aspects of human disease. Indeed,
several transgenic mouse lines have now been developed that
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express mutant genes implicated in human PD.While these trans-
genic mice display anatomical and physiological abnormalities,
many of them show only subtle phenotypes that are not associated
with a loss of dopaminergic neurons, the traditional pathologi-
cal hallmark of PD (Fleming et al., 2005; Melrose et al., 2006).
Furthermore, the question of how broadly the specific models
will apply to all of PD remains. For example, there is considerable
interest in developing drugs that target leucine-rich repeat kinase-
2 (LRRK2) activity, in its mutant form, a known genetic con-
tributor to PD (Deng et al., 2012) and it seems likely that in
such specific cases, the LRRK2 animal models could be useful for
therapeutic testing. However, the general relevance of the LRRK2
animal models for PD is unclear. As such, it is unclear that these
models will rapidly replace the chemical models that have shown
such significant impact on understanding and treating PD to date.
CONSIDERATION OF PD ETIOLOGY AS MULTIFACTORIAL
Unlike the traditional view of a single disease state, it has been
suggested that PD may be a collection of multiple diseases that
share a common phenotype. It is unclear if each genetic, chemical
and environmental form of the disease are all part of a com-
mon route to a single disease or alternatively, a series of different
disease forms with a similar ultimate outcome. If the latter is
true, then it seems unlikely that there will be an one-size-fits
all therapy. It also raises questions as to whether clinical tri-
als that include the entire spectrum of Parkinson’s sufferers are
necessarily the best sample population and if diagnosis and test-
ing of treatments should ultimately include genetic testing and
individualized therapies.
The low penetrance of PD and the variable involvement
of alpha-synuclein and/or Lewy bodies suggests that many
factors, in combination or as “multiple hits,” is required for the
degeneration characteristic of PD (Sulzer, 2007). This multiple
hit hypothesis argues that in addition to mechanisms such as
oxidative stress, excitotoxicity, inflammation etc., multiple risk
factors including genetic predisposition, toxin exposure, aging,
and potentially other unknown factors, all interact to produce
what we classify as PD.
This model explores the possibility that some forms of the dis-
ease may in fact have an early, possibly even prenatal, onset as
a result of specific disruption to neuronal development. It has
been suggested that early damage to the dopaminergic system
via various developmental genes such as Nurr1 and Pitx3 could
result in patients born with a lower number of DA neurons or
a higher than normal vulnerability to a second environmental
factor (Weidong et al., 2009). It is known that the nigrostriatal
DA system is able to compensate for significant losses of DA
neurons in the SN to allow the CNS to maintain normal motor
function (Calne and Zigmond, 1991). In addition, DA neurons
have evolved multiple mechanisms to protect themselves against
cytosolic DA-related cellular stress from which it has been sug-
gested their unique structure and function predisposes them to
(Sulzer, 2007). Thus, when there are multiple insults, as suggested
to occur in PD, the system can no longer regulate itself.
In line with the multi-hit hypothesis, genetic animal mod-
els of PD may represent early disease stages or an increase in
vulnerability to secondary factors. Indeed, when coupled with
environmental risk factors, including neurotoxins as used in PD
research, these transgenic mouse lines often display marked neu-
rodegeneration (Oliveira et al., 2003). Therefore the use of animal
models that employ both genetics and toxins may be beneficial to
the investigation of a disease that is fast becoming identified as
one with a mutlifactorial etiology.
CLINICAL TRIALS
In order to identify more efficacious drugs for treating PD symp-
toms and/or halting neurodegeneration, advancements in clinical
trial design will also be required, specifically, the way in which PD
and its progression is diagnosed and monitored. The discovery of
biomarkers that relate to specific disease stages will significantly
aid in this area by allowing inclusion of more precisely defined
patient populations in clinical trials and more accurate assess-
ment of novel therapies against precise staging. Major efforts are
underway in this area, but we note here that the same issue applies
to biomarkers as to clinical trials generally with a one-size-fits-all
disease marker likely hard to identify. Disease diversity may also
need to be taken more strongly into consideration in clinical tri-
als. Just as APOE4 genetic status is now used to stratify patients
when analyzing clinical trials in Alzheimer’s disease (Salloway
et al., 2014), patients in PD trials may also need to be grouped
genetically in post-hoc analyses. This may allow for the identifi-
cation of subsets of patients in which the therapy may be showing
the most promise.
Testing of neuroprotective agents directed to prevent disease
progression will remain a particular challenge in light of these
issues. It is likely that the efficacy of a given disease-modifying
therapy in a given individual will depend on the specific disease
cause and disease stage. It is a widely accepted problem that PD is
not commonly diagnosed until approximately 80% of DA neu-
rons are already lost and, if Braak staging (section Beyond the
midbrain dopamine system) is generally correct, damage to other
regions will have begun even before DA loss. It is therefore likely
that achieving an unequivocal disease-modifying result against
specific outcomes in a short 6–12 month trial in a population of
PD patients, each with different disease causes and each at dif-
ferent disease stages, is going to remain difficult. The challenge
is compounded by a lack of strategies for early disease detection,
likely resulting in neuroprotective drugs being tested too late to
induce significant benefit.
This became evident during the ADAGIO (Attenuation of
Disease Progression with Azilect Given Once-Daily) clinical trial
of rasagiline (Olanow et al., 2009), which utilized a complex
“randomized start” design that has not truly been validated
and furthermore assumes that the course of PD is fairly well
defined. The outcome of that trial remains ambiguous, with a US
Food and Drug Administration advisory committee voting unan-
imously against including a disease-modifying effect of rasagiline
as one of its indications (Food and Drug Administration, 2011).
Similarly, the Deprenyl and Tocopherol Antioxidative Therapy
of Parkinsonism (DATATOP) study initially described the effects
of selegiline as neuroprotective, only to be confounded later
by the recognized symptomatic effects (Parkinson Study Group,
1989, 1993). These outcomes are likely to reflect, in part, all
the issues outlined above, including challenges in identifying an
unequivocal result in a relatively short trial and in such a diverse
population.
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In sum, until improvements in issues of disease diversity,
stage, and monitoring are resolved it remains likely that current
design of clinical trials to test both effective symptomatic and
true disease-modifying therapies is going to remain a significant
challenge.
BEYOND THE MIDBRAIN DOPAMINE SYSTEM
Recent evidence has provided a framework in which the stag-
ing of PD can be reconsidered and therefore the validity of
solely focusing on DA reassessed. Research conducted by Braak
and colleagues (2002) demonstrated a correlation between insol-
uble alpha-synuclein deposition, its location, and the stage of
the disease (Braak et al., 2002). They proposed that the neu-
ropathological profile of PD progresses in a characteristic and
non-random manner, and more importantly in a largely caudo-
rostral direction over time (Braak et al., 2002, 2003, 2004).
Known as Braak staging, six stages of neuropathology represent
“pre-symptomatic” and “symptomatic” phases. In stages 1 and
2 alpha-synuclein deposits begin in the dorsal motor nucleus of
the vagus nerve, olfactory bulb and medulla, with no noticeable
motor symptoms. In stage 3 the pathology progresses from the
brainstem but remains subcortical, with deposits found in the
midbrain and basal forebrain. In stage 4, deposits are found in
cortical regions and cell loss is evident in the SN. It is at this
stage that individuals may display the first symptoms consistent
with Parkinsonism. Finally, stages 5 and 6 show few remain-
ing neuromelanin-positive cells in the SN and alpha-synuclein
deposits begin to invade the neocortex, with patients displaying
severe motor symptoms and cognitive dysfunction. It is impor-
tant to note that the validity, accuracy and clinical relevance
of Braak staging is controversial, with many critics publishing
numerous studies describing individual differences in pathol-
ogy and symptomology, indicating that not all cases fit into this
caudo-rostral progression (Attems and Jellinger, 2008; Parkkinen
et al., 2008; Jellinger, 2009). Regardless, the concept of a pro-
gression of degeneration and dysfunction that begins outside the
dopaminergic system warrants significant thought and investiga-
tion. Furthermore, such staging not only allows for the devel-
opment of biomarkers for the early detection of PD, in itself an
extremely necessary avenue to pursue, but highlights the need
to consider how animal models may recapitulate these stages. A
recent study has provided a means for thinking about this issue
(Luk et al., 2012).
Finally, there continues to be ever increasing understanding
of the BG circuits that regulate movement. By using ever-refined
methods and techniques the understanding of the circuit and
the role of the major brain regions involved is being refined
(Draganski et al., 2008; Kravitz et al., 2010; Redgrave et al., 2010;
Ryczko et al., 2013). The consequence of this increased under-
standing of how the BG functions is going to inevitably lead to
refined approaches to treatment.
HOPE FOR NEUROPROTECTIVE THERAPIES
When examined as a whole, the treatment strategies outlined
in this review display clinical outcomes that are skewed toward
symptomatic relief of the motor symptoms of PD, or reducing
LIDs. Clearly the next stage of therapeutic development is to
identify disease-modifying treatments that offer neuroprotection.
Progress in understanding the onset of PD has provided a number
of candidate targets for neuroprotective and neurorescue inter-
ventions. As mentioned previously, the only potential disease-
modifying agent identified in clinical trials to date is rasagiline,
but the conflicting results and subsequent FDA analysis pre-
dicts that there will unlikely be clear evidence that rasagiline will
be able to halt the progression of PD (Parkinson Study Group,
2004; Olanow et al., 2009). Nevertheless, results in animal mod-
els to date provide some promise that disease-modifying thera-
pies may be emerging, in particular mGluR antagonists (section
Metabotropic glutamate receptors), calcium channel antagonists
(section Calcium channel blockers), and GLP-1 based therapeu-
tics (section Glucagon-like peptide 1 (GLP-1) agonist). Finally,
the role of inflammation (section Anti-inflammatories) offers
an interesting avenue that will potentially reveal new therapeu-
tics going forward. Meanwhile, it remains unclear, as to whether
growth factor treatments, especially if delivered by gene ther-
apy, will also offer promise (section Neurotrophic factors). It
seems likely that much more needs to be understood of the spe-
cific mechanisms, processes and events underlying cell loss in PD
before significant progress can be made in this area.
CONCLUSIONS
The major advances in treating PD have come from our under-
standing of the mechanisms of the disease, much of which
emerged from animal models. With the introduction of L-Dopa
as a PD therapy approximately 50 years ago, the outlook and
quality of life for patients dramatically changed and a number of
potential treatments have since been identified. The new wave of
treatments coming through in recent times has involved moving
away from dopamine–mimetic treatments to a set of treatments
that work in entirely new ways. Together with the extensive work
in progress directed to both understand and treat the disease,
we may be in the midst of a revolution in understanding and
treating PD.
AUTHOR CONTRIBUTIONS
Both Sandy Stayte and Bryce Vissel were responsible for all
research, writing and editing of the manuscript.
SOURCES OF SUPPORT
This work was supported by Bill Gruy; Iain S. Gray Foundation;
Stanley and John Roth; David King; Doug Battersby; Geoff and
Dawn Dixon; Geoffrey Towner; Tony and Vivian Howland-Rose;
Walter and Edith Sheldon; Gleneagle Securities; Amadeus Energy
Ltd.; Nick and Melanie Kell; Wicking Trust and the Mason
Foundation; and SpinalCure Australia.
ACKNOWLEDGMENTS
We thank the members of the Neurodegenerative Disorders
Group for constructive comments on the manuscript and helpful
discussions.
REFERENCES
Aarsland, D., Larsen, J. P., Lim, N. G., Janvin, C., Karlsen, K., Tandberg, E., et al.
(1999). Range of neuropsychiatric disturbances in patients with Parkinson’s
disease. J. Neurol. Neurosurg. Psychiatry 67, 492–496. doi: 10.1136/jnnp.67.4.492
Abdipranoto-Cowley, A., Park, J. S., Croucher, D., Daniel, J., Henshall, S., Galbraith,
S., et al. (2009). Activin A is essential for neurogenesis following neurodegener-
ation. Stem Cells 27, 1330–1346. doi: 10.1002/stem.80
Frontiers in Neuroscience | Neuropharmacology May 2014 | Volume 8 | Article 113 | 20
Stayte and Vissel Advances in Parkinson’s disease therapeutics
Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy
of basal ganglia disorders. Trends Neurosci. 12, 366–375. doi: 10.1016/0166-
2236(89)90074-X
Albin, R. L., Young, A. B., and Penney, J. B. (1995). The functional anatomy of
disorders of the basal ganglia. Trends Neurosci. 18, 63–64. doi: 10.1016/0166-
2236(95)80020-3
Aldenkamp, A. P., Baker, G., Mulder, O. G., Chadwick, D., Cooper, P., Doelman, J.,
et al. (2000). A multicenter, randomized clinical study to evaluate the effect on
cognitive function of topiramate compared with valproate as add-on therapy to
carbamazepine in patients with partial-onset seizures. Epilepsia 41, 1167–1178.
doi: 10.1111/j.1528-1157.2000.tb00322.x
Amgen. (2005). Following Complete Review of Phase 2 Trial Data Amgen Confirms
Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings,
Patient Safety, Drove Decision. Thousand Oaks: AMGEN.
Amor, S., Puentes, F., Baker, D., and Van Der Valk, P. (2010). Inflammation in
neurodegenerative diseases. Immunology 129, 154–169. doi: 10.1111/j.1365-
2567.2009.03225.x
Arai, R., Karasawa, N., Geffard, M., and Nagatsu, I. (1995). L-DOPA is converted
to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling
immunofluorescence study. Neurosci. Lett. 195, 195–198. doi: 10.1016/0304-
3940(95)11817-G
Armentero, M. T., Fancellu, R., Nappi, G., Bramanti, P., and Blandini, F. (2006).
Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigros-
triatal degeneration while inducing selective metabolic changes in the basal
ganglia circuitry in a rodent model of Parkinson’s disease. Neurobiol. Dis. 22,
1–9. doi: 10.1016/j.nbd.2005.09.010
Asanuma, M., and Miyazaki, I. (2007). Common anti-inflammatory drugs are
potentially therapeutic for Parkinson’s disease? Exp. Neurol. 206, 172–178. doi:
10.1016/j.expneurol.2007.05.006
Attems, J., and Jellinger, K. A. (2008). The dorsal motor nucleus of the vagus is not
an obligatory trigger site of Parkinson’s disease. Neuropathol. Appl. Neurobiol.
34, 466–467. doi: 10.1111/j.1365-2990.2008.00937.x
Aubin, N., Curet, O., Deffois, A., and Carter, C. (1998). Aspirin and salicylate
protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71,
1635–1642. doi: 10.1046/j.1471-4159.1998.71041635.x
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund,
T., et al. (2013). Exenatide and the treatment of patients with Parkinson’s
disease. J. Clin. Invest. 123, 2730–2736. doi: 10.1172/JCI68295
Banati, R. B., Daniel, S. E., and Blunt, S. B. (1998). Glial pathology but absence of
apoptotic nigral neurons in long-standing Parkinson’s disease. Mov. Disord. 13,
221–227. doi: 10.1002/mds.870130205
Bara-Jimenez,W., Bibbiani, F., Morris, M. J., Dimitrova, T., Sherzai, A., Mouradian,
M. M., et al. (2005). Effects of serotonin 5-HT1A agonist in advanced
Parkinson’s disease.Mov. Disord. 20, 932–936. doi: 10.1002/mds.20370
Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M.,
et al. (2003). Adenosine A(2A) receptor antagonist treatment of Parkinson’s
disease. Neurology 61, 293–296. doi: 10.1212/01.WNL.0000073136.00548.D4
Barcia, C., Ros, C. M., Annese, V., Gomez, A., Ros-Bernal, F., Aguado-Yera,
D., et al. (2011). IFN-gamma signaling, with the synergistic contribution of
TNF-alpha, mediates cell specific microglial and astroglial activation in experi-
mental models of Parkinson’s disease. Cell Death Dis. 2:e142. doi: 10.1038/cddis.
2011.17
Barnum, C. J., Bhide, N., Lindenbach, D., Surrena, M. A., Goldenberg, A. A.,
Tignor, S., et al. (2012). Effects of noradrenergic denervation on L-DOPA-
induced dyskinesia and its treatment by alpha- and beta-adrenergic recep-
tor antagonists in hemiparkinsonian rats. Pharmacol. Biochem. Behav. 100,
607–615. doi: 10.1016/j.pbb.2011.09.009
Bartus, R. T., Baumann, T. L., Siffert, J., Herzog, C. D., Alterman, R.,
Boulis, N., et al. (2013). Safety/feasibility of targeting the substantia nigra
with AAV2-neurturin in Parkinson patients. Neurology 80, 1698–1701. doi:
10.1212/WNL.0b013e3182904faa
Bartus, R. T., Herzog, C. D., Chu, Y., Wilson, A., Brown, L., Siffert, J., et al. (2011).
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between
Parkinson’s disease and nonhuman primate brains.Mov. Disord. 26, 27–36. doi:
10.1002/mds.23442
Beal, M. F. (2010). Parkinson’s disease: a model dilemma. Nature 466, S8–S10. doi:
10.1038/466S8a
Ben-Shachar, D., Eshel, G., Finberg, J. P., and Youdim, M. B. (1991). The
iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced
degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441–1444.
doi: 10.1111/j.1471-4159.1991.tb11444.x
Ben-Shachar, D., Eshel, G., Riederer, P., and Youdim, M. B. (1992). Role of
iron and iron chelation in dopaminergic-induced neurodegeneration: impli-
cation for Parkinson’s disease. Ann. Neurol. 32(Suppl.), S105–S110. doi:
10.1002/ana.410320718
Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., et al. (2011).
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized
controlled trials.Mov. Disord. 26, 1243–1250. doi: 10.1002/mds.23616
Berg, D., and Hochstrasser, H. (2006). Iron metabolism in Parkinsonian syn-
dromes.Mov. Disord. 21, 1299–1310. doi: 10.1002/mds.21020
Bezard, E., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Bjorklund, A., et al. (2013).
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-
induced dyskinesia.Mov. Disord. 28, 1088–1096. doi: 10.1002/mds.25366
Bishnoi, M., Chopra, K., and Kulkarni, S. K. (2006). Involvement of adenosiner-
gic receptor system in an animal model of tardive dyskinesia and associated
behavioural, biochemical and neurochemical changes. Eur. J. Pharmacol. 552,
55–66. doi: 10.1016/j.ejphar.2006.09.010
Bishnoi,M., Chopra, K., and Kulkarni, S. K. (2007). Theophylline, adenosine recep-
tor antagonist prevents behavioral, biochemical and neurochemical changes
associated with an animal model of tardive dyskinesia. Pharmacol. Rep. 59,
181–191.
Blanchet, P. J., Konitsiotis, S., Whittemore, E. R., Zhou, Z. L., Woodward, R. M.,
and Chase, T. N. (1999). Differing effects of N-methyl-D-aspartate receptor
subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-
phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290, 1034–1040.
Blandini, F., Armentero, M. T., andMartignoni, E. (2008). The 6-hydroxydopamine
model: news from the past. Parkinsonism. Relat. Disord. 14(Suppl. 2),
S124–S129. doi: 10.1016/j.parkreldis.2008.04.015
Blandini, F., Nappi, G., Tassorelli, C., and Martignoni, E. (2000). Functional
changes of the basal ganglia circuitry in Parkinson’s disease. Prog. Neurobiol.
62, 63–88. doi: 10.1016/S0301-0082(99)00067-2
Bonci, A., Grillner, P., Mercuri, N. B., and Bernardi, G. (1998). L-Type cal-
cium channels mediate a slow excitatory synaptic transmission in rat midbrain
dopaminergic neurons. J. Neurosci. 18, 6693–6703.
Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., and Meco, G. (1994).
Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 17, 73–82.
doi: 10.1097/00002826-199402000-00008
Boulet, S., Mounayar, S., Poupard, A., Bertrand, A., Jan, C., Pessiglione, M., et al.
(2008). Behavioral recovery in MPTP-treated monkeys: neurochemical mech-
anisms studied by intrastriatal microdialysis. J. Neurosci. 28, 9575–9584. doi:
10.1523/JNEUROSCI.3465-08.2008
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., and
Rub, U. (2002). Staging of the intracerebral inclusion body pathology associated
with idiopathic Parkinson’s disease (preclinical and clinical stages). J. Neurol.
249(Suppl. 3), III, 1–5. doi: 10.1007/s00415-002-1301-4
Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak,
E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease.
Neurobiol. Aging 24, 197–211. doi: 10.1016/S0197-4580(02)00065-9
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., and Del Tredici, K. (2004).
Stages in the development of Parkinson’s disease-related pathology. Cell Tissue.
Res. 318, 121–134. doi: 10.1007/s00441-004-0956-9
Breysse, N., Amalric, M., and Salin, P. (2003). Metabotropic glutamate 5 recep-
tor blockade alleviates akinesia by normalizing activity of selective basal-ganglia
structures in parkinsonian rats. J. Neurosci. 23, 8302–8309.
Breysse, N., Baunez, C., Spooren, W., Gasparini, F., and Amalric, M. (2002).
Chronic but not acute treatment with a metabotropic glutamate 5 recep-
tor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
J. Neurosci. 22, 5669–5678.
Burchiel, K. J., Anderson, V. C., Favre, J., and Hammerstad, J. P. (1999).
Comparison of pallidal and subthalamic nucleus deep brain stimulation for
advanced Parkinson’s disease: results of a randomized, blinded pilot study.
Neurosurgery 45, 1375–1382; discussion: 1382–1374.
Burn, D. J. (2002). Beyond the iron mask: towards better recognition and treatment
of depression associated with Parkinson’s disease.Mov. Disord. 17, 445–454. doi:
10.1002/mds.10114
Calne, D. B., and Zigmond, M. J. (1991). Compensatory mechanisms in degenera-
tive neurologic diseases. Insights from parkinsonism. Arch. Neurol. 48, 361–363.
doi: 10.1001/archneur.1991.00530160025009
www.frontiersin.org May 2014 | Volume 8 | Article 113 | 21
Stayte and Vissel Advances in Parkinson’s disease therapeutics
Calon, F., Dridi, M., Hornykiewicz, O., Bedard, P. J., Rajput, A. H., and Di
Paolo, T. (2004). Increased adenosine A2A receptors in the brain of Parkinson’s
disease patients with dyskinesias. Brain 127, 1075–1084. doi: 10.1093/brain/
awh128
Carlsson, M., and Carlsson, A. (1989). The NMDA antagonist MK-801 causes
marked locomotor stimulation in monoamine-depleted mice. J. Neural.
Transm. 75, 221–226. doi: 10.1007/BF01258633
Carroll, R. C., and Zukin, R. S. (2002). NMDA-receptor trafficking and target-
ing: implications for synaptic transmission and plasticity. Trends. Neurosci. 25,
571–577. doi: 10.1016/S0166-2236(02)02272-5
Carta, M., and Bezard, E. (2011). Contribution of pre-synaptic mecha-
nisms to L-DOPA-induced dyskinesia. Neuroscience 198, 245–251. doi:
10.1016/j.neuroscience.2011.07.070
Carta, M., Carlsson, T., Kirik, D., and Bjorklund, A. (2007). Dopamine released
from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinso-
nian rats. Brain 130, 1819–1833. doi: 10.1093/brain/awm082
Ceregene (2013). Ceregene Reports Data from Parkinson’s Disease Phase 2b Study.
San Diego. Available online at: http://www.ceregene.com/press_041913.asp
[Accessed 20 July 2013].
Chan, C. S., Gertler, T. S., and Surmeier, D. J. (2010). A molecular basis
for the increased vulnerability of substantia nigra dopamine neurons in
aging and Parkinson’s disease. Mov. Disord. 25(Suppl. 1), S63–S70. doi:
10.1002/mds.22801
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., et al. (2007).
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease.Nature
447, 1081–1086. doi: 10.1038/nature05865
Chen, J. F., Xu, K., Petzer, J. P., Staal, R., Xu, Y. H., Beilstein, M., et al. (2001).
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a
model of Parkinson’s disease. J. Neurosci. 21, RC143.
Choi, D. W. (1988). Glutamate neurotoxicity and diseases of the nervous system.
Neuron 1, 623–634. doi: 10.1016/0896-6273(88)90162-6
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W.
J., Hawkins, R. A., et al. (2009). Safety and tolerability of putaminal
AADC gene therapy for Parkinson disease. Neurology 73, 1662–1669. doi:
10.1212/WNL.0b013e3181c29356
Cicchetti, F., Lapointe, N., Roberge-Tremblay, A., Saint-Pierre, M., Jimenez, L.,
Ficke, B. W., et al. (2005). Systemic exposure to paraquat and maneb models
early Parkinson’s disease in young adult rats. Neurobiol. Dis. 20, 360–371. doi:
10.1016/j.nbd.2005.03.018
Clark, I., Atwood, C., Bowen, R., Paz-Filho, G., and Vissel, B. (2012). Tumor
necrosis factor-induced cerebral insulin resistance in Alzheimer’s disease
links numerous treatment rationales. Pharmacol. Rev. 64, 1004–1026. doi:
10.1124/pr.112.005850
Clark, I. A., Alleva, L. M., and Vissel, B. (2010). The roles of TNF
in brain dysfunction and disease. Pharmacol. Ther. 128, 519–548. doi:
10.1016/j.pharmthera.2010.08.007
Clark, I. A., and Vissel, B. (2013). Treatment implications of the altered cytokine-
insulin axis in neurodegenerative disease. Biochem. Pharmacol. 86, 862–871. doi:
10.1016/j.bcp.2013.07.030
Coccurello, R., Breysse, N., and Amalric, M. (2004). Simultaneous blockade of
adenosine A2A andmetabotropic glutamatemGlu5 receptors increase their effi-
cacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29,
1451–1461. doi: 10.1038/sj.npp.1300444
Collier, T. J., and Sortwell, C. E. (1999). Therapeutic potential of nerve growth
factors in Parkinson’s disease.Drugs Aging. 14, 261–287. doi: 10.2165/00002512-
199914040-00003
Conn, P. J., Battaglia, G., Marino, M. J., and Nicoletti, F. (2005). Metabotropic
glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 6,
787–798. doi: 10.1038/nrn1763
Corasaniti, M. T., Strongoli, M. C., Rotiroti, D., Bagetta, G., and Nistico, G.
(1998). Paraquat: a useful tool for the in vivo study of mechanisms of neu-
ronal cell death. Pharmacol. Toxicol. 83, 1–7. doi: 10.1111/j.1600-0773.1998.
tb01434.x
Cozzi, A., Rovelli, E., Frizzale, G., Campanella, A., Amendola, M., Arosio,
P., et al. (2010). Oxidative stress and cell death in cells expressing L-
ferritin variants causing neuroferritinopathy. Neurobiol. Dis. 37, 77–85. doi:
10.1016/j.nbd.2009.09.009
Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A.,
et al. (2013). Pimavanserin for patients with Parkinson’s disease psychosis:
a randomised, placebo-controlled phase 3 trial. Lancet 383, 533–540. doi:
10.1016/S0140-6736(13)62106-6
Dauer, W., and Przedborski, S. (2003). Parkinson’s disease: mechanisms and
models. Neuron 39, 889–909. doi: 10.1016/S0896-6273(03)00568-3
Dekundy, A., Pietraszek, M., Schaefer, D., Cenci, M. A., and Danysz, W. (2006).
Effects of group I metabotropic glutamate receptors blockade in experi-
mental models of Parkinson’s disease. Brain Res. Bull. 69, 318–326. doi:
10.1016/j.brainresbull.2005.12.009
Deng, X., Choi, H. G., Buhrlage, S. J., and Gray, N. S. (2012). Leucine-rich repeat
kinase 2 inhibitors: a patent review (2006 - 2011). Expert Opin. Ther. Pat. 22,
1415–1426. doi: 10.1517/13543776.2012.729041
Derkach, V. A., Oh, M. C., Guire, E. S., and Soderling, T. R. (2007). Regulatory
mechanisms of AMPA receptors in synaptic plasticity. Nat. Rev. Neurosci. 8,
101–113. doi: 10.1038/nrn2055
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., et al.
(2014). Targeting chelatable iron as a therapeutic modality in Parkinson’s
disease. Antioxid. Redox. Signal. doi: 10.1089/ars.2013.5593. [Epub ahead of
print].
Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999). The glutamate
receptor ion channels. Pharmacol. Rev. 51, 7–61.
Draganski, B., Kherif, F., Kloppel, S., Cook, P. A., Alexander, D. C., Parker,
G. J., et al. (2008). Evidence for segregated and integrative connectiv-
ity patterns in the human Basal Ganglia. J. Neurosci. 28, 7143–7152. doi:
10.1523/JNEUROSCI.1486-08.2008
Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M.,
et al. (2004). Clozapine improves dyskinesias in Parkinson disease:
a double-blind, placebo-controlled study. Neurology 62, 381–388. doi:
10.1212/01.WNL.0000110317.52453.6C
Durif, F., Vidailhet, M., Assal, F., Roche, C., Bonnet, A. M., and Agid, Y. (1997).
Low-dose clozapine improves dyskinesias in Parkinson’s disease. Neurology 48,
658–662. doi: 10.1212/WNL.48.3.658
Dutra, R. C., Andreazza, A. P., Andreatini, R., Tufik, S., and Vital, M.
A. (2002). Behavioral effects of MK-801 on reserpine-treated mice. Prog.
Neuropsychopharmacol. Biol. Psychiatry 26, 487–495. doi: 10.1016/S0278-
5846(01)00295-0
Duty, S., and Jenner, P. (2011). Animal models of Parkinson’s disease: a source of
novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164,
1357–1391. doi: 10.1111/j.1476-5381.2011.01426.x
Eberling, J. L., Kells, A. P., Pivirotto, P., Beyer, J., Bringas, J., Federoff, H. J., et al.
(2009). Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal
pathway in parkinsonian rhesus monkeys. Hum. Gene. Ther. 20, 511–518. doi:
10.1089/hum.2008.201
Eggert, K., Squillacote, D., Barone, P., Dodel, R., Katzenschlager, R., Emre, M.,
et al. (2010). Safety and efficacy of perampanel in advanced Parkinson’s dis-
ease: a randomized, placebo-controlled study. Mov. Disord. 25, 896–905. doi:
10.1002/mds.22974
El Yacoubi, M., Ledent, C., Menard, J. F., Parmentier, M., Costentin, J., and
Vaugeois, J. M. (2000). The stimulant effects of caffeine on locomotor behaviour
in mice are mediated through its blockade of adenosine A(2A) receptors. Br. J.
Pharmacol. 129, 1465–1473. doi: 10.1038/sj.bjp.0703170
Emborg, M. E., Carbon, M., Holden, J. E., During, M. J., Ma, Y., Tang, C.,
et al. (2007). Subthalamic glutamic acid decarboxylase gene therapy: changes
in motor function and cortical metabolism. J. Cereb. Blood. Flow. Metab. 27,
501–509. doi: 10.1038/sj.jcbfm.9600364
Emre, M. (2003). Dementia associated with Parkinson’s disease. Lancet Neurol. 2,
229–237. doi: 10.1016/S1474-4422(03)00351-X
Emre, M., Tsolaki, M., Bonuccelli, U., Destee, A., Tolosa, E., Kutzelnigg, A., et al.
(2010). Memantine for patients with Parkinson’s disease dementia or dementia
with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet
Neurol. 9, 969–977. doi: 10.1016/S1474-4422(10)70194-0
Engber, T. M., Papa, S. M., Boldry, R. C., and Chase, T. N. (1994). NMDA receptor
blockade reverses motor response alterations induced by levodopa. Neuroreport
5, 2586–2588. doi: 10.1097/00001756-199412000-00045
Erinoff, L., and Snodgrass, S. R. (1986). Effects of adult or neonatal treatment
with 6-hydroxydopamine or 5,7-dihydroxytryptamine on locomotor activity,
monoamine levels, and response to caffeine. Pharmacol. Biochem. Behav. 24,
1039–1045. doi: 10.1016/0091-3057(86)90453-3
Eslamboli, A., Cummings, R. M., Ridley, R. M., Baker, H. F., Muzyczka, N.,
Burger, C., et al. (2003). Recombinant adeno-associated viral vector (rAAV)
Frontiers in Neuroscience | Neuropharmacology May 2014 | Volume 8 | Article 113 | 22
Stayte and Vissel Advances in Parkinson’s disease therapeutics
delivery of GDNF provides protection against 6-OHDA lesion in the com-
mon marmoset monkey (Callithrix jacchus). Exp. Neurol. 184, 536–548. doi:
10.1016/j.expneurol.2003.08.007
Factor, S., Mark, M. H., Watts, R., Struck, L., Mori, A., Ballerini, R., et al. (2010). A
long-term study of istradefylline in subjects with fluctuating Parkinson’s disease.
Parkinsonism. Relat. Disord. 16, 423–426. doi: 10.1016/j.parkreldis.2010.02.014
Factor, S. A., Wolski, K., Togasaki, D. M., Huyck, S., Cantillon, M., Ho, T. W., et al.
(2013). Long-term safety and efficacy of preladenant in subjects with fluctuating
Parkinson’s disease.Mov. Disord. 28, 817–820. doi: 10.1002/mds.25395
Fan, D. S., Ogawa, M., Fujimoto, K. I., Ikeguchi, K., Ogasawara, Y., Urabe, M., et al.
(1998). Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotrans-
duction of striatum with tyrosine hydroxylase and aromatic L-amino acid
decarboxylase genes using two separate adeno-associated virus vectors. Hum.
Gene. Ther. 9, 2527–2535. doi: 10.1089/hum.1998.9.17-2527
Ferger, B., Teismann, P., Earl, C. D., Kuschinsky, K., and Oertel, W. H. (1999).
Salicylate protects against MPTP-induced impairments in dopaminergic neu-
rotransmission at the striatal and nigral level in mice. Naunyn. Schmiedebergs.
Arch. Pharmacol. 360, 256–261. doi: 10.1007/s002109900079
Fleming, S. M., Fernagut, P. O., and Chesselet, M. F. (2005). Genetic mouse
models of parkinsonism: strengths and limitations. NeuroRx 2, 495–503. doi:
10.1602/neurorx.2.3.495
Food and Drug Administration (2011). Azilect (Rasagiline Mesylate). Silver Spring,
MD.
Fornai, F., Di Poggio, A. B., Pellegrini, A., Ruggieri, S., and Paparelli, A. (2007).
Noradrenaline in Parkinson’s disease: from disease progression to current ther-
apeutics. Curr. Med. Chem. 14, 2330–2334. doi: 10.2174/092986707781745550
Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Crossman, A. R., and Brotchie,
J. M. (2001). Neural mechanisms underlying peak-dose dyskinesia induced
by levodopa and apomorphine are distinct: evidence from the effects of the
alpha(2) adrenoceptor antagonist idazoxan. Mov. Disord. 16, 642–650. doi:
10.1002/mds.1148
Gagne, J. J., and Power, M. C. (2010). Anti-inflammatory drugs and
risk of Parkinson disease: a meta-analysis. Neurology 74, 995–1002. doi:
10.1212/WNL.0b013e3181d5a4a3
Gal, S., Zheng, H., Fridkin, M., and Youdim, M. B. (2005). Novel multifunctional
neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurode-
generative diseases. In vivo selective brain monoamine oxidase inhibition and
prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95,
79–88. doi: 10.1111/j.1471-4159.2005.03341.x
Gao, H. M., and Hong, J. S. (2008). Why neurodegenerative diseases are progres-
sive: uncontrolled inflammation drives disease progression. Trends. Immunol.
29, 357–365. doi: 10.1016/j.it.2008.05.002
Garcia-Borreguero, D., Larrosa, O., and Bravo, M. (2003). Parkinson’s disease and
sleep. Sleep. Med. Rev. 7, 115–129. doi: 10.1053/smrv.2002.0229
Gasmi, M., Brandon, E. P., Herzog, C. D., Wilson, A., Bishop, K. M., Hofer, E. K.,
et al. (2007a). AAV2-mediated delivery of human neurturin to the rat nigros-
triatal system: long-term efficacy and tolerability of CERE-120 for Parkinson’s
disease. Neurobiol. Dis. 27, 67–76. doi: 10.1016/j.nbd.2007.04.003
Gasmi, M., Herzog, C. D., Brandon, E. P., Cunningham, J. J., Ramirez, G. A.,
Ketchum, E. T., et al. (2007b). Striatal delivery of neurturin by CERE-120,
an AAV2 vector for the treatment of dopaminergic neuron degeneration in
Parkinson’s disease.Mol. Ther. 15, 62–68. doi: 10.1038/sj.mt.6300010
Gerfen, C. R. (1992). The neostriatal mosaic: multiple levels of compartmen-
tal organization. Trends. Neurosci. 15, 133–139. doi: 10.1016/0166-2236(92)
90355-C
Gerhardt, G. A., Cass, W. A., Huettl, P., Brock, S., Zhang, Z., and Gash, D. M.
(1999). GDNF improves dopamine function in the substantia nigra but not the
putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res. 817, 163–171.
doi: 10.1016/S0006-8993(98)01244-X
Goetz, C. G., Damier, P., Hicking, C., Laska, E., Muller, T., Olanow, C. W.,
et al. (2007). Sarizotan as a treatment for dyskinesias in Parkinson’s dis-
ease: a double-blind placebo-controlled trial. Mov. Disord. 22, 179–186. doi:
10.1002/mds.21226
Gomez-Mancilla, B., and Bedard, P. J. (1993). Effect of nondopaminergic drugs on
L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol.
16, 418–427. doi: 10.1097/00002826-199310000-00004
Graham, W. C., Robertson, R. G., Sambrook, M. A., and Crossman, A. R.
(1990). Injection of excitatory amino acid antagonists into the medial palli-
dal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated
primate reverses motor symptoms of parkinsonism. Life Sci. 47, PL91–PL97.
doi: 10.1016/0024-3205(90)90376-3
Graybiel, A. M. (1990). Neurotransmitters and neuromodulators in the
basal ganglia. Trends Neurosci. 13, 244–254. doi: 10.1016/0166-2236(90)
90104-I
Grunblatt, E., Mandel, S., Maor, G., and Youdim, M. B. (2001). Gene expres-
sion analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model
of Parkinson’s disease using cDNA microarray: effect of R-apomorphine.
J. Neurochem. 78, 1–12. doi: 10.1046/j.1471-4159.2001.00397.x
Gryder, D. S., and Rogawski, M. A. (2003). Selective antagonism of GluR5 kainate-
receptor-mediated synaptic currents by topiramate in rat basolateral amygdala
neurons. J. Neurosci. 23, 7069–7074.
Hara, K., Tohyama, I., Kimura, H., Fukuda, H., Nakamura, S., and Kameyama, M.
(1987). Reversible serotoninergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and
immunohistochemical approaches. Brain Res. 410, 371–374. doi: 10.1016/0006-
8993(87)90341-6
Hardingham, G. E., and Bading, H. (2010). Synaptic versus extrasynaptic NMDA
receptor signalling: implications for neurodegenerative disorders. Nat. Rev.
Neurosci. 11, 682–696. doi: 10.1038/nrn2911
Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., andWhitton,
P. S. (2008). Glucagon-like peptide 1 receptor stimulation reverses key deficits
in distinct rodent models of Parkinson’s disease. J. Neuroinflammation 5:19. doi:
10.1186/1742-2094-5-19
Harman, D. (1972). The biologic clock: the mitochondria? J. Am. Geriatr. Soc. 20,
145–147.
Harms, A. S., Barnum, C. J., Ruhn, K. A., Varghese, S., Trevino, I., Blesch, A., et al.
(2010). Delayed dominant-negative TNF gene therapy halts progressive loss of
nigral dopaminergic neurons in a rat model of Parkinson’s disease. Mol. Ther.
19, 46–52. doi: 10.1038/mt.2010.217
Hauser, R. A. (2009). Levodopa: past, present, and future. Eur. Neurol. 62, 1–8. doi:
10.1159/000215875
Hauser, R. A., Cantillon, M., Pourcher, E., Micheli, F., Mok, V., Onofrj, M., et al.
(2011). Preladenant in patients with Parkinson’s disease and motor fluctua-
tions: a phase 2, double-blind, randomised trial. Lancet Neurol. 10, 221–229.
doi: 10.1016/S1474-4422(11)70012-6
Hauser, R. A., Shulman, L. M., Trugman, J. M., Roberts, J. W., Mori, A., Ballerini,
R., et al. (2008). Study of istradefylline in patients with Parkinson’s dis-
ease on levodopa with motor fluctuations. Mov. Disord. 23, 2177–2185. doi:
10.1002/mds.22095
Henry, B., Crossman, A. R., and Brotchie, J. M. (1998). Characterization of
enhanced behavioral responses to L-DOPA following repeated administra-
tion in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Exp.
Neurol. 151, 334–342. doi: 10.1006/exnr.1998.6819
Henry, B., Fox, S. H., Peggs, D., Crossman, A. R., and Brotchie, J. M. (1999).
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and
enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate
model of Parkinson’s disease. Mov. Disord. 14, 744–753.
Herzog, C. D., Dass, B., Holden, J. E., Stansell, J. 3rd., Gasmi, M., Tuszynski, M. H.,
et al. (2007). Striatal delivery of CERE-120, an AAV2 vector encoding human
neurturin, enhances activity of the dopaminergic nigrostriatal system in aged
monkeys.Mov. Disord. 22, 1124–1132. doi: 10.1002/mds.21503
Hettinger, B. D., Lee, A., Linden, J., and Rosin, D. L. (2001). Ultrastructural localiza-
tion of adenosine A2A receptors suggests multiple cellular sites for modulation
of GABAergic neurons in rat striatum. J. Comp. Neurol. 431, 331–346. doi:
10.1002/1096-9861(20010312)431:3%3C331::AID-CNE1074%3E3.0.CO;2-W
Hill, M. P., and Brotchie, J. M. (1999). The adrenergic receptor agonist, clonidine,
potentiates the anti-parkinsonian action of the selective kappa-opioid recep-
tor agonist, enadoline, in the monoamine-depleted rat. Br. J. Pharmacol. 128,
1577–1585. doi: 10.1038/sj.bjp.0702943
Hirsch, E. C., Vyas, S., and Hunot, S. (2012). Neuroinflammation in
Parkinson’s disease. Parkinsonism. Relat. Disord. 18(Suppl. 1), S210–S212. doi:
10.1016/S1353-8020(11)70065-7
Hodgson, R. A., Bertorelli, R., Varty, G. B., Lachowicz, J. E., Forlani, A., Fredduzzi,
S., et al. (2009). Characterization of the potent and highly selective A2A receptor
antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1 -
piperazinyl]ethyl] - 2 - (2 - furanyl) - 7H - pyrazolo[4,3 - e][1,2,4]triazolo[1,5-c]
pyrimidin-5-amine] in rodent models of movement disorders and depression.
J. Pharmacol. Exp. Ther. 330, 294–303. doi: 10.1124/jpet.108.149617
www.frontiersin.org May 2014 | Volume 8 | Article 113 | 23
Stayte and Vissel Advances in Parkinson’s disease therapeutics
Hollmann, M., and Heinemann, S. (1994). Cloned glutamate receptors. Annu. Rev.
Neurosci. 17, 31–108. doi: 10.1146/annurev.ne.17.030194.000335
Huang, Z. L., Qu, W. M., Eguchi, N., Chen, J. F., Schwarzschild, M. A., Fredholm,
B. B., et al. (2005). Adenosine A2A, but not A1, receptors mediate the arousal
effect of caffeine. Nat. Neurosci. 8, 858–859. doi: 10.1038/nn1491
Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S.
H., et al. (2014). UWA-121, a mixed dopamine and serotonin re-uptake
inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dysk-
inesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
Neuropharmacology 82C, 76–87. doi: 10.1016/j.neuropharm.2014.01.012
Ikeda, K., Kurokawa, M., Aoyama, S., and Kuwana, Y. (2002). Neuroprotection
by adenosine A2A receptor blockade in experimental models of Parkinson’s
disease. J. Neurochem. 80, 262–270. doi: 10.1046/j.0022-3042.2001.00694.x
Ilijic, E., Guzman, J. N., and Surmeier, D. J. (2011). The L-type channel antag-
onist isradipine is neuroprotective in a mouse model of Parkinson’s disease.
Neurobiol. Dis. 43, 364–371. doi: 10.1016/j.nbd.2011.04.007
Invernizzi, R. W., Garavaglia, C., and Samanin, R. (2003). The alpha 2-
adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in
rats independent of striatal dopamine release: role of serotonergic mechanisms.
Neuropsychopharmacology 28, 872–879. doi: 10.1038/sj.npp.13001191300119
Ishiwata, K., Mishina, M., Kimura, Y., Oda, K., Sasaki, T., and Ishii, K. (2005).
First visualization of adenosine A(2A) receptors in the human brain by
positron emission tomography with [11C]TMSX. Synapse 55, 133–136. doi:
10.1002/syn.20099
Jackson-Lewis, V., Blesa, J., and Przedborski, S. (2012). Animal models of
Parkinson’s disease. Parkinsonism. Relat. Disord. 18 (Suppl. 1), S183–S185. doi:
10.1016/S1353-8020(11)70057-8
Jellinger, K. A. (2009). A critical evaluation of current staging of alpha-synuclein
pathology in Lewy body disorders. Biochim. Biophys. Acta 1792, 730–740. doi:
10.1016/j.bbadis.2008.07.006
Jenner, P., Mori, A., Hauser, R., Morelli, M., Fredholm, B. B., and Chen, J. F. (2009).
Adenosine, adenosine A 2A antagonists, and Parkinson’s disease. Parkinsonism.
Relat. Disord. 15, 406–413. doi: 10.1016/j.parkreldis.2008.12.006
Johnston, L. C., Eberling, J., Pivirotto, P., Hadaczek, P., Federoff, H. J., Forsayeth,
J., et al. (2009). Clinically relevant effects of convection-enhanced delivery
of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus
monkeys. Hum. Gene. Ther. 20, 497–510. doi: 10.1089/hum.2008.137
Johnston, T. H., Fox, S. H., Piggott, M. J., Savola, J. M., and Brotchie, J. M.
(2010). The alpha(2) adrenergic antagonist fipamezole improves quality of
levodopa action in Parkinsonian primates. Mov. Disord. 25, 2084–2093. doi:
10.1002/mds.23172
Kachroo, A., Irizarry, M. C., and Schwarzschild, M. A. (2010). Caffeine pro-
tects against combined paraquat and maneb-induced dopaminergic neuron
degeneration. Exp. Neurol. 223, 657–661. doi: 10.1016/j.expneurol.2010.02.007
Kachroo, A., Orlando, L. R., Grandy, D. K., Chen, J. F., Young, A. B., and
Schwarzschild, M. A. (2005). Interactions between metabotropic glutamate 5
and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci. 25,
10414–10419. doi: 10.1523/JNEUROSCI.3660-05.2005
Kalda, A., Yu, L., Oztas, E., and Chen, J. F. (2006). Novel neuroprotection by caf-
feine and adenosine A(2A) receptor antagonists in animal models of Parkinson’s
disease. J. Neurol. Sci. 248, 9–15. doi: 10.1016/j.jns.2006.05.003
Kanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K., Nakamura, J., Kase, H., et al.
(1998). Adenosine A2A antagonist: a novel antiparkinsonian agent that does not
provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43, 507–513. doi:
10.1002/ana.410430415
Kang, S., Cooper, G., Dunne, S. F., Dusel, B., Luan, C. H., Surmeier, D. J., (2012).
CaV1.3-selective L-type calcium channel antagonists as potential new therapeu-
tics for Parkinson’s disease. Nat. Commun. 3, 1146. doi: 10.1038/ncomms2149
Kannari, K., Kurahashi, K., Tomiyama, M., Maeda, T., Arai, A., Baba, M.,
et al. (2002). [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-
DOPA-induced dyskinesia in patients with Parkinson’s disease]. Shinkei. 54,
133–137.
Kanner, A. M., Wuu, J., Faught, E., Tatum, W. O. T., Fix, A., and French, J.
A. (2003). A past psychiatric history may be a risk factor for topiramate-
related psychiatric and cognitive adverse events. Epilepsy. Behav. 4, 548–552. doi:
10.1016/j.yebeh.2003.07.007
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., et al.
(2007). Safety and tolerability of gene therapy with an adeno-associated virus
(AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial.
Lancet 369, 2097–2105. doi: 10.1016/S0140-6736(07)60982-9
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., et al.
(2003). Genetic or pharmacological iron chelation prevents MPTP-induced
neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37,
899–909. doi: 10.1016/S0896-6273(03)00126-0
Kaur, S., Ozer, H., and Starr, M. (1997). MK 801 reverses haloperidol-induced
catalepsy from both striatal and extrastriatal sites in the rat brain. Eur. J.
Pharmacol. 332, 153–160. doi: 10.1016/S0014-2999(97)01078-9
Kaur, S., and Starr, M. S. (1995). Antiparkinsonian action of dextromethor-
phan in the reserpine-treated mouse. Eur. J. Pharmacol. 280, 159–166. doi:
10.1016/0014-2999(95)00200-5
Kearney, J. A., Becker, J. B., Frey, K. A., and Albin, R. L. (1998). The role of
nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation.
Neuroscience 87, 881–891.
Kearney, J. A., Frey, K. A., and Albin, R. L. (1997). Metabotropic glutamate agonist-
induced rotation: a pharmacological, FOS immunohistochemical, and [14C]-2-
deoxyglucose autoradiographic study. J. Neurosci. 17, 4415–4425.
Kelsey, J. E., Mague, S. D., Pijanowski, R. S., Harris, R. C., Kleckner, N. W., and
Matthews, R. T. (2004). NMDA receptor antagonists ameliorate the stepping
deficits produced by unilateral medial forebrain bundle injections of 6-OHDA
in rats. Psychopharmacology (Berl.) 175, 179–188. doi: 10.1007/s00213-004-
1799-5
Kessels, H. W., and Malinow, R. (2009). Synaptic AMPA receptor plasticity and
behavior. Neuron 61, 340–350. doi: 10.1016/j.neuron.2009.01.015
Kirik, D., Rosenblad, C., and Bjorklund, A. (2000a). Preservation of a functional
nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion
model depends on the site of administration of the trophic factor. Eur. J.
Neurosci. 12, 3871–3882. doi: 10.1046/j.1460-9568.2000.00274.x
Kirik, D., Rosenblad, C., Bjorklund, A., and Mandel, R. J. (2000b). Long-term
rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastri-
atal but not intranigral transduction promotes functional regeneration in the
lesioned nigrostriatal system. J. Neurosci. 20, 4686–4700.
Kish, S. J. (2003). Biochemistry of Parkinson’s disease: is a brain serotonergic
deficiency a characteristic of idiopathic Parkinson’s disease? Adv. Neurol. 91,
39–49.
Klein, C., and Westenberger, A. (2012). Genetics of Parkinson’s disease. Cold.
Spring. Harb. Perspect. Med. 2:a008888. doi: 10.1101/cshperspect.a008888
Klockgether, T., Turski, L., Honore, T., Zhang, Z. M., Gash, D. M., Kurlan, R.,
et al. (1991). The AMPA receptor antagonist NBQX has antiparkinsonian effects
in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30,
717–723. doi: 10.1002/ana.410300513
Knott, C., Stern, G., and Wilkin, G. P. (2000). Inflammatory regulators in
Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.Mol. Cell
Neurosci. 16, 724–739. doi: 10.1006/mcne.2000.0914
Kobylecki, C., Burn, D. J., Kass-Iliyya, L., Kellett, M. W., Crossman, A. R., and
Silverdale, M. A. (2014). Randomized clinical trial of topiramate for levodopa-
induced dyskinesia in Parkinson’s disease. Parkinsonism. Relat. Disord. 240,
452–455. doi: 10.1016/j.parkreldis.2014.01.016
Kobylecki, C., Hill, M. P., Crossman, A. R., and Ravenscroft, P. (2011). Synergistic
antidyskinetic effects of topiramate and amantadine in animal models of
Parkinson’s disease.Mov. Disord. 26, 2354–2363. doi: 10.1002/mds.23867
Konieczny, J., Ossowska, K., Schulze, G., Coper, H., and Wolfarth, S. (1999).
L-701,324, a selective antagonist at the glycine site of the NMDA receptor, coun-
teracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berl.)
143, 235–243. doi: 10.1007/s002130050942
Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., and Chase, T. N. (2000).
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP
monkeys. Neurology. 54, 1589–1595. doi: 10.1212/WNL.54.8.1589
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A., Stansell, J. 3rd., Gasmi,
M., et al. (2006). Delivery of neurturin by AAV2 (CERE-120)-mediated gene
transfer provides structural and functional neuroprotection and neurorestora-
tion in MPTP-treated monkeys. Ann. Neurol. 60, 706–715. doi: 10.1002/ana.
21032
Kordower, J. H., Palfi, S., Chen, E. Y., Ma, S. Y., Sendera, T., Cochran, E. J., et al.
(1999). Clinicopathological findings following intraventricular glial-derived
neurotrophic factor treatment in a patient with Parkinson’s disease.Ann. Neurol.
46, 419–424.
Frontiers in Neuroscience | Neuropharmacology May 2014 | Volume 8 | Article 113 | 24
Stayte and Vissel Advances in Parkinson’s disease therapeutics
Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J.,
Johnson, E. M. Jr., et al. (1996). Neurturin, a relative of glial-cell-line-derived
neurotrophic factor. Nature 384, 467–470. doi: 10.1038/384467a0
Koutsilieri, E., and Riederer, P. (2007). Excitotoxicity and new antiglutamatergic
strategies in Parkinson’s disease and Alzheimer’s disease. Parkinsonism. Relat.
Disord. 13(Suppl. 3), S329–S331. doi: 10.1016/S1353-8020(08)70025-7
Kravitz, A. V., Freeze, B. S., Parker, P. R., Kay, K., Thwin, M. T., Deisseroth, K., et al.
(2010). Regulation of parkinsonian motor behaviours by optogenetic control of
basal ganglia circuitry. Nature 466, 622–626. doi: 10.1038/nature09159
Kumar, R., Lozano, A. M., Kim, Y. J., Hutchison, W. D., Sime, E., Halket, E.,
et al. (1998). Double-blind evaluation of subthalamic nucleus deep brain
stimulation in advanced Parkinson’s disease. Neurology 51, 850–855. doi:
10.1212/WNL.51.3.850
Kurkowska-Jastrzebska, I., Babiuch, M., Joniec, I., Przybylkowski, A., Czlonkowski,
A., and Czlonkowska, A. (2002). Indomethacin protects against neurode-
generation caused by MPTP intoxication in mice. Int. Immunopharmacol. 2,
1213–1218. doi: 10.1016/S1567-5769(02)00078-4
Kuwajima, M., Dehoff, M. H., Furuichi, T., Worley, P. F., Hall, R. A., and Smith, Y.
(2007). Localization and expression of group I metabotropic glutamate recep-
tors in themouse striatum, globus pallidus, and subthalamic nucleus: regulatory
effects of MPTP treatment and constitutive Homer deletion. J. Neurosci. 27,
6249–6260. doi: 10.1523/JNEUROSCI.3819-06.2007
Kyowa Hakko Kirin Co Ltd. (2008). Kyowa Hakko Receives Not Approvable
Letter from FDA for Istradefylline (KW-6002) [Media Release]. Available online
at: http://www.kyowa-kirin.com/news_releases/kyowa/2008/er080228_01.html
[Accessed 10 December 2013].
Kyowa Hakko Kirin Co Ltd. (2013). Approval for Manufacturing and
Marketing of NOURIAST Tablets 20mg, a Novel Antiparkinsonian
Agent [Media Release]. Available online: http://www.kyowa-kirin.com/
news_releases/2013/e20130325_04.html [Accessed 10 December 2013].
Lan, J., and Jiang, D. H. (1997). Desferrioxamine and vitamin E protect against
iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm. 104,
469–481. doi: 10.1007/BF01277665
Lange, K. W., Loschmann, P. A., Sofic, E., Burg, M., Horowski, R., Kalveram,
K. T., et al. (1993). The competitive NMDA antagonist CPP protects sub-
stantia nigra neurons from MPTP-induced degeneration in primates. Naunyn.
Schmiedebergs. Arch. Pharmacol. 348, 586–592. doi: 10.1007/BF00167234
Latini, S., and Pedata, F. (2001). Adenosine in the central nervous system: release
mechanisms and extracellular concentrations. J. Neurochem 79, 463–484. doi:
10.1046/j.1471-4159.2001.00607.x
Lau, C. G., and Zukin, R. S. (2007). NMDA receptor trafficking in synaptic
plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8, 413–426. doi:
10.1038/nrn2153
Lavoie, B., and Parent, A. (1990). Immunohistochemical study of the serotoninergic
innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299,
1–16. doi: 10.1002/cne.902990102
Lee, B., Lee, H., Nam, Y. R., Oh, J. H., Cho, Y. H., and Chang, J. W. (2005).
Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat
parkinsonian models. Gene. Ther. 12, 1215–1222. doi: 10.1038/sj.gt.3302520
Lees, A., Fahn, S., Eggert, K. M., Jankovic, J., Lang, A., Micheli, F., et al. (2012).
Perampanel, an AMPA antagonist, found to have no benefit in reducing
“off” time in Parkinson’s disease. Mov. Disord. 27, 284–288. doi: 10.1002/mds.
23983
Leff, S. E., Spratt, S. K., Snyder, R. O., and Mandel, R. J. (1999). Long-term restora-
tion of striatal L-aromatic amino acid decarboxylase activity using recombinant
adeno-associated viral vector gene transfer in a rodent model of Parkinson’s
disease. Neuroscience 92, 185–196. doi: 10.1016/S0306-4522(98)00741-6
Lewitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., et al.
(2008). Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces
“off” time in Parkinson’s disease: a double-blind, randomized, multicenter
clinical trial (6002-US-005). Ann. Neurol. 63, 295–302. doi: 10.1002/ana.21315
Lewitt, P. A., Hauser, R. A., Lu, M., Nicholas, A. P., Weiner, W., Coppard,
N., et al. (2012). Randomized clinical trial of fipamezole for dyskine-
sia in Parkinson disease (FJORD study). Neurology 79, 163–169. doi:
10.1212/WNL.0b013e31825f0451
Lewitt, P. A., Li, J., Lu, M., Beach, T. G., Adler, C. H., and Guo, L. (2013). 3-
hydroxykynurenine and other Parkinson’s disease biomarkers discovered by
metabolomic analysis.Mov. Disord. 28, 1653–1660. doi: 10.1002/mds.25555
Lewitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar,
E. N., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson’s disease:
a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10,
309–319. doi: 10.1016/S1474-4422(11)70039-4
Li, X., Jankovic, J., and Le, W. (2011). Iron chelation and neuroprotection in neu-
rodegenerative diseases. J. Neural. Transm. 118, 473–477. doi: 10.1007/s00702-
010-0518-0
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., et al.
(2009). GLP-1 receptor stimulation preserves primary cortical and dopamin-
ergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc.
Natl. Acad. Sci. U.S.A. 106, 1285–1290. doi: 10.1073/pnas.0806720106
Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., and Collins, F. (1993). GDNF: a
glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.
Science 260, 1130–1132. doi: 10.1126/science.8493557
Lin, S. C., Lin, K. J., Hsiao, I. T., Hsieh, C. J., Lin, W. Y., Lu, C. S., et al. (2013).
In vivo detection of monoaminergic degeneration in early Parkinson disease by
18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET. J. Nucl. Med. 55, 73–79.
doi: 10.2967/jnumed.113.121897
Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., and Cenci, M. A.
(2010). L-DOPA-induced dopamine efflux in the striatum and the substantia
nigra in a rat model of Parkinson’s disease: temporal and quantitative rela-
tionship to the expression of dyskinesia. J. Neurochem. 112, 1465–1476. doi:
10.1111/j.1471-4159.2009.06556.x
Lipscombe, D., Helton, T. D., and Xu, W. (2004). L-type calcium channels: the low
down. J. Neurophysiol. 92, 2633–2641. doi: 10.1152/jn.00486.2004
Loschmann, P. A., Kunow, M., and Wachtel, H. (1992). Synergism of NBQX with
dopamine agonists in the 6-OHDA rat model of Parkinson’s disease. J. Neural.
Transm. Suppl. 38, 55–64.
Loschmann, P. A., Lange, K.W., Kunow,M., Rettig, K. J., Jahnig, P., Honore, T., et al.
(1991). Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist
CPP with L-dopa in models of Parkinson’s disease. J. Neural. Transm. Park. Dis.
Dement. Sect. 3, 203–213. doi: 10.1007/BF02259538
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q.,
(2012). Pathological alpha-synuclein transmission initiates Parkinson-like neu-
rodegeneration in nontransgenic mice. Science 338, 949–953. doi: 10.1126/sci-
ence.1227157
Luo, J., Kaplitt, M. G., Fitzsimons, H. L., Zuzga, D. S., Liu, Y., Oshinsky, M. L.,
et al. (2002). Subthalamic GAD gene therapy in a Parkinson’s disease rat model.
Science 298, 425–429. doi: 10.1126/science.1074549
Magerkurth, C., Schnitzer, R., and Braune, S. (2005). Symptoms of autonomic fail-
ure in Parkinson’s disease: prevalence and impact on daily life. Clin. Auton. Res.
15, 76–82. doi: 10.1007/s10286-005-0253-z
Mandhane, S. N., Chopde, C. T., and Ghosh, A. K. (1997). Adenosine A2 recep-
tors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 328,
135–141. doi: 10.1016/S0014-2999(97)83039-7
Marin, C., Papa, S., Engber, T. M., Bonastre, M., Tolosa, E., and Chase, T. N. (1996).
MK-801 prevents levodopa-inducedmotor response alterations in parkinsonian
rats. Brain Res. 736, 202–205. doi: 10.1016/0006-8993(96)00693-2
Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J. B., Medhurst, A.
D., and Dexter, D. T. (2009). Relationship between microglial activation and
dopaminergic neuronal loss in the substantia nigra: a time course study in a
6-hydroxydopamine model of Parkinson’s disease. J. Neurochem. 110, 966–975.
doi: 10.1111/j.1471-4159.2009.06189.x
Marks, W. J. Jr., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N.,
et al. (2010). Gene delivery of AAV2-neurturin for Parkinson’s disease: a
double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164–1172. doi:
10.1016/S1474-4422(10)70254-4
Marks, W. J. Jr., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R.
A., et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-
120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic
Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 7, 400–408. doi:
10.1016/S1474-4422(08)70065-6
Marsala, S. Z., Gioulis, M., Ceravolo, R., and Tinazzi, M. (2012). A sys-
tematic review of catechol-0-methyltransferase inhibitors: efficacy and
safety in clinical practice. Clin. Neuropharmacol. 35, 185–190. doi:
10.1097/WNF.0b013e31825c034a
Mastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G.,
Cheng, D., et al. (2009). A novel transferrin/TfR2-mediated mitochondrial iron
www.frontiersin.org May 2014 | Volume 8 | Article 113 | 25
Stayte and Vissel Advances in Parkinson’s disease therapeutics
transport system is disrupted in Parkinson’s disease.Neurobiol. Dis. 34, 417–431.
doi: 10.1016/j.nbd.2009.02.009
Mavridis, M., Degryse, A. D., Lategan, A. J., Marien, M. R., and Colpaert,
F. C. (1991). Effects of locus coeruleus lesions on parkinsonian signs, stri-
atal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine in monkeys: a possible role for the locus coeruleus
in the progression of Parkinson’s disease. Neuroscience 41, 507–523. doi:
10.1016/0306-4522(91)90345-O
McAllister, K. H. (1996). The competitive NMDA receptor antagonist SDZ 220-581
reverses haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 314, 307–311.
doi: 10.1016/S0014-2999(96)00576-6
Mcgeer, P. L., Itagaki, S., Boyes, B. E., and Mcgeer, E. G. (1988). Reactive microglia
are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s
disease brains. Neurology 38, 1285–1291. doi: 10.1212/WNL.38.8.1285
Mcgeer, P. L., Schwab, C., Parent, A., and Doudet, D. (2003). Presence
of reactive microglia in monkey substantia nigra years after
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54,
599–604. doi: 10.1002/ana.10728
Mcmillan, P. J., White, S. S., Franklin, A., Greenup, J. L., Leverenz, J. B., Raskind, M.
A., et al. (2011). Differential response of the central noradrenergic nervous sys-
tem to the loss of locus coeruleus neurons in Parkinson’s disease and Alzheimer’s
disease. Brain Res. 1373, 240–252. doi: 10.1016/j.brainres.2010.12.015
Meco, G., Fabrizio, E., Di Rezze, S., Alessandri, A., and Pratesi, L. (2003).
Mirtazapine in L-dopa-induced dyskinesias. Clin. Neuropharmacol. 26,
179–181. doi: 10.1097/00002826-200307000-00005
Meco, G., Stirpe, P., Edito, F., Purcaro, C., Valente, M., Bernardi, S., et al. (2009).
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
J. Neural. Transm. 116, 881–884. doi: 10.1007/s00702-009-0231-z
Mehta, A. K., and Ticku, M. K. (1990). Role of N-methyl-D-aspartate (NMDA)
receptors in experimental catalepsy in rats. Life Sci. 46, 37–42. doi:
10.1016/0024-3205(90)90054-U
Melrose, H. L., Lincoln, S. J., Tyndall, G. M., and Farrer, M. J. (2006). Parkinson’s
disease: a rethink of rodent models. Exp. Brain Res. 173, 196–204. doi:
10.1007/s00221-006-0461-3
Mertens, J., Stuber, K.,Wunderlich, P., Ladewig, J., Kesavan, J. C., Vandenberghe, R.,
et al. (2013). APP Processing in human pluripotent stem cell-derived neurons
is resistant to NSAID-based gamma-secretase modulation. Stem. Cell. Reports 1,
491–498. doi: 10.1016/j.stemcr.2013.10.011
Michael, J. Fox Foundation. (2014). Drug that May Slow Parkinson’s Progression
Granted $23 Million from NIH for Phase III testing. New York, NY: Michael
J. Fox Foundation. Available online at: https://www.michaeljfox.org/foun-
dation/news-detail.php?podcast-drug-that-may-slow-parkinson-progression–
granted-23-million-from-nih-for-phase-iii [Accessed 4 April 2014].
Michael, J. Fox Foundation. (2012). Addex Adds it Up for Parkinson’s Patients. New
York, NY: The Michael J. Fox Foundation.
Mirza, B., Hadberg, H., Thomsen, P., and Moos, T. (2000). The absence
of reactive astrocytosis is indicative of a unique inflammatory process in
Parkinson’s disease. Neuroscience 95, 425–432. doi: 10.1016/S0306-4522(99)
00455-8
Mitra, S., Chakrabarti, N., and Bhattacharyya, A. (2011). Differential regional
expression patterns of alpha-synuclein, TNF-alpha, and IL-1beta; and variable
status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment.
J. Neuroinflammation. 8:163. doi: 10.1186/1742-2094-8-163
Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P.,
Larson, P., et al. (2014). Long-term evaluation of a phase 1 study of AADC
gene therapy for Parkinson’s disease. Hum. Gene. Ther. 23, 377–381. doi:
10.1089/hum.2011.220
Miyasaki, J. M. (2010). Evidence-based initiation of dopaminergic therapy in
Parkinson’s disease. J. Neurol. 257, S309–S313. doi: 10.1007/s00415-010-
5718-x
Miyoshi, Y., Zhang, Z., Ovadia, A., Lapchak, P. A., Collins, F., Hilt, D., et al. (1997).
Glial cell line-derived neurotrophic factor-levodopa interactions and reduc-
tion of side effects in parkinsonian monkeys. Ann. Neurol. 42, 208–214. doi:
10.1002/ana.410420212
Mizuno, Y., and Kondo, T. (2013). Adenosine A2A receptor antagonist istradefylline
reduces daily OFF time in Parkinson’s disease.Mov. Disord. 28, 1138–1141. doi:
10.1002/mds.25418
Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M.,
et al. (1994). Interleukin-1 beta, interleukin-6, epidermal growth factor and
transforming growth factor-alpha are elevated in the brain from parkinsonian
patients. Neurosci. Lett. 180, 147–150. doi: 10.1016/0304-3940(94)90508-8
Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel-Doring, F.,
Ebentheuer, J., et al. (2013). Total CSF alpha-synuclein is lower in de novo
Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44–48. doi:
10.1016/j.neulet.2012.11.004
Moreau, C., Delval, A., Tiffreau, V., Defebvre, L., Dujardin, K., Duhamel, A.,
et al. (2013). Memantine for axial signs in Parkinson’s disease: a randomised,
double-blind, placebo-controlled pilot study. J. Neurol. Neurosurg. Psychiatry.
84, 552–555. doi: 10.1136/jnnp-2012-303182
Morin, N., Gregoire, L., Morissette, M., Desrayaud, S., Gomez-Mancilla, B.,
Gasparini, F., et al. (2013a). MPEP, an mGlu5 receptor antagonist, reduces the
development of L-DOPA-induced motor complications in de novo parkinso-
nian monkeys: biochemical correlates. Neuropharmacology 66, 355–364. doi:
10.1016/j.neuropharm.2012.07.036
Morin, N., Morissette, M., Gregoire, L., Gomez-Mancilla, B., Gasparini, F.,
and Di Paolo, T. (2013b). Chronic treatment with MPEP, an mGlu5 recep-
tor antagonist, normalizes basal ganglia glutamate neurotransmission in l-
DOPA-treated parkinsonian monkeys. Neuropharmacology 73C, 216–231. doi:
10.1016/j.neuropharm.2013.05.028
Morris, G. P., Clark, I. A., Zinn, R., and Vissel, B. (2013). Microglia: a new fron-
tier for synaptic plasticity, learning and memory, and neurodegenerative disease
research. Neurobiol. Learn. Mem. 105, 40–53. doi: 10.1016/j.nlm.2013.07.002
Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., et al. (2008).
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-
DOPA-induced dyskinesia. Brain 131, 3380–3394. doi: 10.1093/brain/awn235
Muramatsu, S., Fujimoto, K., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., et al.
(2010). A phase I study of aromatic L-amino acid decarboxylase gene therapy
for Parkinson’s disease.Mol. Ther. 18, 1731–1735. doi: 10.1038/mt.2010.135
Nash, J. E., Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Mcguire, S., et al.
(2000). Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset
model of Parkinson’s disease. Exp. Neurol. 165, 136–142. doi: 10.1006/exnr.
2000.7444
Niswender, C. M., and Conn, P. J. (2010). Metabotropic glutamate receptors: phys-
iology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322.
doi: 10.1146/annurev.pharmtox.011008.145533
Nowak, P., Bortel, A., Dabrowska, J., Biedka, I., Slomian, G., Roczniak, W., et al.
(2008). Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral
responses and L-dopa derived extracellular dopamine in dopamine-denervated
rat striatum. Neurotox. Res. 13, 231–240. doi: 10.1007/BF03033506
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws,
E. R. Jr., et al. (2003). Randomized, double-blind trial of glial cell line-
derived neurotrophic factor (GDNF) in PD. Neurology 60, 69–73. doi: 10.1212/
WNL.60.1.69
Oiwa, Y., Yoshimura, R., Nakai, K., and Itakura, T. (2002). Dopaminergic neuropro-
tection and regeneration by neurturin assessed by using behavioral, biochemical
and histochemical measurements in a model of progressive Parkinson’s disease.
Brain Res. 947, 271–283. doi: 10.1016/S0006-8993(02)02934-7
Olanow, C. W., Damier, P., Goetz, C. G., Mueller, T., Nutt, J., Rascol, O.,
et al. (2004). Multicenter, open-label, trial of sarizotan in Parkinson dis-
ease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin.
Neuropharmacol. 27, 58–62. doi: 10.1097/00002826-200403000-00003
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., et al.
(2009). A double-blind, delayed-start trial of rasagiline in Parkinson’s disease.
N. Engl. J. Med. 361, 1268–1278. doi: 10.1056/NEJMoa0809335
Oliveira, S. A., Scott, W. K., Martin, E. R., Nance, M. A., Watts, R. L., Hubble,
et al. (2003). Parkinmutations and susceptibility alleles in late-onset Parkinson’s
disease. Ann. Neurol. 53, 624–629. doi: 10.1002/ana.10524
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., et al.
(2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based
gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2
trial. Lancet 383, 1138–1146. doi: 10.1016/S0140-6736(13)61939-X
Palfi, S., Leventhal, L., Chu, Y., Ma, S. Y., Emborg, M., Bakay, R., et al. (2002).
Lentivirally delivered glial cell line-derived neurotrophic factor increases the
number of striatal dopaminergic neurons in primate models of nigrostriatal
degeneration. J. Neurosci. 22, 4942–4954.
Paoletti, P., Bellone, C., and Zhou, Q. (2013). NMDA receptor subunit diver-
sity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev.
Neurosci. 14, 383–400. doi: 10.1038/nrn3504
Frontiers in Neuroscience | Neuropharmacology May 2014 | Volume 8 | Article 113 | 26
Stayte and Vissel Advances in Parkinson’s disease therapeutics
Paoletti, P., and Neyton, J. (2007). NMDA receptor subunits: function and phar-
macology. Curr. Opin. Pharmacol. 7, 39–47. doi: 10.1016/j.coph.2006.08.011
Parkinson Study Group. (1989). Effect of deprenyl on the progression of disability
in early Parkinson’s disease. The Parkinson Study Group. N. Engl. J. Med. 321,
1364–1371. doi: 10.1056/NEJM198911163212004
Parkinson Study Group. (1993). Effects of tocopherol and deprenyl on the progres-
sion of disability in early Parkinson’s disease. N. Engl. J. Med. 328, 176–183. doi:
10.1056/NEJM199301213280305
Parkinson Study Group. (2004). A controlled, randomized, delayed-start study
of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566. doi:
10.1001/archneur.61.4.561
Parkinson Study Group (2013). Phase II safety, tolerability, and dose selection study
of isradipine as a potential disease-modifying intervention in early Parkinson’s
disease (STEADY-PD). Mov. Disord. 28, 1823–1831. doi: 10.1002/mds.
25639
Parkkinen, L., Pirttila, T., and Alafuzoff, I. (2008). Applicability of current stag-
ing/categorization of alpha-synuclein pathology and their clinical relevance.
Acta. Neuropathol. 115, 399–407. doi: 10.1007/s00401-008-0346-6
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf,
O., et al. (2013). Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev.
Neurol. 9, 131–140. doi: 10.1038/nrneurol.2013.10
Perez-Lloret, S., and Rascol, O. (2010). Dopamine receptor agonists for the treat-
ment of early or advanced Parkinson’s disease. CNS Drugs 24, 941–968. doi:
10.2165/11537810-000000000-00000
Perez-Otano, I., and Ehlers,M. D. (2005). Homeostatic plasticity andNMDA recep-
tor trafficking. Trends. Neurosci. 28, 229–238. doi: 10.1016/j.tins.2005.03.004
Peroutka, S. J. (1995). 5-HT receptors: past, present and future. Trends. Neurosci.
18, 68–69. doi: 10.1016/0166-2236(95)80023-U
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., and Greig, N. H.
(2002a). Protection and reversal of excitotoxic neuronal damage by glucagon-
like peptide-1 and exendin-4. J Pharmacol. Exp. Ther. 302, 881–888. doi:
10.1124/jpet.102.037481
Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T., Egan, J. M., et al. (2002b).
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve
growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther.
300, 958–966. doi: 10.1124/jpet.300.3.958
Phani, S., Loike, J. D., and Przedborski, S. (2012). Neurodegeneration and
inflammation in Parkinson’s disease. Parkinsonism. Relat. Disord. 18(Suppl. 1),
S207–S209. doi: 10.1016/S1353-8020(11)70064-5
Phinney, A. L., Andringa, G., Bol, J. G., Wolters, E., Van Muiswinkel, F. L., Van
Dam, A. M., et al. (2006). Enhanced sensitivity of dopaminergic neurons to
rotenone-induced toxicity with aging. Parkinsonism. Relat. Disord. 12, 228–238.
doi: 10.1016/j.parkreldis.2005.12.002
Porter, R. H., Greene, J. G., Higgins, D. S. Jr., and Greenamyre, J. T. (1994).
Polysynaptic regulation of glutamate receptors and mitochondrial enzyme
activities in the basal ganglia of rats with unilateral dopamine depletion.
J. Neurosci. 14, 7192–7199.
Potashkin, J. A., Blume, S. R., and Runkle, N. K. (2011). Limitations of
animal models of Parkinson’s disease. Parkinsons. Dis. 2011:658083. doi:
10.4061/2011/658083
Price, D. L., Rockenstein, E., Ubhi, K., Phung, V., Maclean-Lewis, N., Askay, D.,
et al. (2010). Alterations in mGluR5 expression and signaling in Lewy body
disease and in transgenic models of alpha-synucleinopathy–implications for
excitotoxicity. PLoS ONE 5:e14020. doi: 10.1371/journal.pone.0014020
Przedborski, S., Tieu, K., Perier, C., and Vila, M. (2004). MPTP as a mitochondrial
neurotoxic model of Parkinson’s disease. J. Bioenerg. Biomembr. 36, 375–379.
doi: 10.1023/B:JOBB.0000041771.66775.d5
Przedborski, S., and Vila, M. (2003). The 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine mouse model: a tool to explore the pathogenesis of
Parkinson’s disease. Ann. N.Y. Acad. Sci. 991, 189–198. doi: 10.1111/j.1749-
6632.2003.tb07476.x
Rascol, O., Arnulf, I., Peyro-Saint Paul, H., Brefel-Courbon, C., Vidailhet, M.,
Thalamas, C., et al. (2001). Idazoxan, an alpha-2 antagonist, and L-DOPA-
induced dyskinesias in patients with Parkinson’s disease. Mov. Disord. 16,
708–713. doi: 10.1002/mds.1143
Rascol, O., Barone, P., Behari, M., Emre, M., Giladi, N., Olanow, C. W., et al.
(2012). Perampanel in Parkinson disease fluctuations: a double-blind random-
ized trial with placebo and entacapone. Clin. Neuropharmacol. 35, 15–20. doi:
10.1097/WNF.0b013e318241520b
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., et al.
(2009). Peripheral cytokines profile in Parkinson’s disease. Brain Behav. Immun.
23, 55–63. doi: 10.1016/j.bbi.2008.07.003
Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M. C., Lehericy, S.,
Bergman, H., et al. (2010). Goal-directed and habitual control in the basal gan-
glia: implications for Parkinson’s disease. Nat. Rev. Neurosci. 11, 760–772. doi:
10.1038/nrn2915
Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Ben-Shlomo, Y., et al. (2011). Anti-
hypertensive drugs as disease-modifying agents for Parkinson’s disease: evidence
from observational studies and clinical trials. Cochrane. Database. Syst. Rev.
11:CD008535. doi: 10.1002/14651858.CD008535
Ren, X., Zhang, T., Gong, X., Hu, G., Ding, W., and Wang, X. (2013). AAV2-
mediated striatum delivery of human CDNF prevents the deterioration of
midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian
rat model. Exp. Neurol. 248, 148–156. doi: 10.1016/j.expneurol.2013.06.002
Rodnitzky, R. L. (1999). Can calcium antagonists provide a neuroprotective effect
in Parkinson’s disease? Drugs 57, 845–849. doi: 10.2165/00003495-199957060-
00001
Rommelfanger, K. S., Edwards, G. L., Freeman, K. G., Liles, L. C., Miller, G. W.,
and Weinshenker, D. (2007). Norepinephrine loss produces more profound
motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U.S.A. 104,
13804–13809. doi: 10.1073/pnas.0702753104
Rosenblad, C., Kirik, D., Devaux, B., Moffat, B., Phillips, H. S., and Bjorklund,
A. (1999). Protection and regeneration of nigral dopaminergic neurons by
neurturin or GDNF in a partial lesion model of Parkinson’s disease after
administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11,
1554–1566. doi: 10.1046/j.1460-9568.1999.00566.x
Rousselet, E., Joubert, C., Callebert, J., Parain, K., Tremblay, L., Orieux, G., et al.
(2003). Behavioral changes are not directly related to striatal monoamine lev-
els, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice.
Neurobiol. Dis. 14, 218–228. doi: 10.1016/S0969-9961(03)00108-6
Ryczko, D., Gratsch, S., Auclair, F., Dube, C., Bergeron, S., Alpert, M. H., et al.
(2013). Forebrain dopamine neurons project down to a brainstem region
controlling locomotion. Proc. Natl. Acad. Sci. U.S.A. 110, E3235–E3242. doi:
10.1073/pnas.1301125110
Rylander, D., Recchia, A., Mela, F., Dekundy, A., Danysz, W., and Cenci, M. A.
(2009). Pharmacological modulation of glutamate transmission in a rat model
of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear
signaling. J. Pharmacol. Exp. Ther. 330, 227–235. doi: 10.1124/jpet.108.150425
Salamone, J. D., Betz, A. J., Ishiwari, K., Felsted, J., Madson, L., Mirante, B., et al.
(2008). Tremorolytic effects of adenosine A2A antagonists: implications for
parkinsonism. Front. Biosci. 13, 3594–3605. doi: 10.2741/2952
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., et al.
(2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s
disease. N. Engl. J. Med. 370, 322–333. doi: 10.1056/NEJMoa1304839
Samadi, P., Gregoire, L., Morissette, M., Calon, F., Hadj Tahar, A., Dridi,
M., et al. (2008). mGluR5 metabotropic glutamate receptors and
dyskinesias in MPTP monkeys. Neurobiol. Aging 29, 1040–1051. doi:
10.1016/j.neurobiolaging.2007.02.005
Sanchez-Pernaute, R., Ferree, A., Cooper, O., Yu, M., Brownell, A. L., and Isacson,
O. (2004). Selective COX-2 inhibition prevents progressive dopamine neuron
degeneration in a rat model of Parkinson’s disease. J. Neuroinflammation. 1:6.
doi: 10.1186/1742-2094-1-6
Sanchez-Pernaute, R., Harvey-White, J., Cunningham, J., and Bankiewicz, K. S.
(2001). Functional effect of adeno-associated virus mediated gene transfer of
aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned
rats.Mol. Ther. 4, 324–330. doi: 10.1006/mthe.2001.0466
Sauer, H., Rosenblad, C., and Bjorklund, A. (1995). Glial cell line-derived
neurotrophic factor but not transforming growth factor beta 3 prevents
delayed degeneration of nigral dopaminergic neurons following striatal 6-
hydroxydopamine lesion. Proc. Natl. Acad. Sci. U.S.A. 92, 8935–8939. doi:
10.1073/pnas.92.19.8935
Savola, J. M., Hill, M., Engstrom, M., Merivuori, H., Wurster, S., McGuire, S. G.,
et al. (2003). Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antag-
onist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate
model of Parkinson’s disease.Mov. Disord. 18, 872–883. doi: 10.1002/mds.10464
Schapira, A. H. (2011). Monoamine oxidase B inhibitors for the treatment of
Parkinson’s disease: a review of symptomatic and potential disease-modifying
effects. CNS Drugs 25, 1061–1071. doi: 10.2165/11596310-000000000-00000
www.frontiersin.org May 2014 | Volume 8 | Article 113 | 27
Stayte and Vissel Advances in Parkinson’s disease therapeutics
Scholtissen, B., Verhey, F. R., Steinbusch, H. W., and Leentjens, A. F. (2006).
Serotonergic mechanisms in Parkinson’s disease: opposing results from preclin-
ical and clinical data. J. Neural. Transm. 113, 59–73. doi: 10.1007/s00702-005-
0368-3
Schuster, S., Doudnikoff, E., Rylander, D., Berthet, A., Aubert, I., Ittrich,
C., et al. (2009). Antagonizing L-type Ca2+ channel reduces develop-
ment of abnormal involuntary movement in the rat model of L-3,4-
dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry. 65, 518–526. doi:
10.1016/j.biopsych.2008.09.008
Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., and Youdim, M. B.
(2004). Neuroprotection by a novel brain permeable iron chelator, VK-28,
against 6-hydroxydopamine lession in rats. Neuropharmacology 46, 254–263.
doi: 10.1016/j.neuropharm.2003.09.005
Sherer, T. B., Betarbet, R., Kim, J. H., and Greenamyre, J. T. (2003). Selective
microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci.
Lett. 341, 87–90. doi: 10.1016/S0304-3940(03)00172-1
Shiozaki, S., Ichikawa, S., Nakamura, J., Kitamura, S., Yamada, K., and Kuwana,
Y. (1999). Actions of adenosine A2A receptor antagonist KW-6002 on
drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Psychopharmacology (Berl.) 147, 90–95. doi: 10.1007/s002130051146
Silverdale, M. A., Nicholson, S. L., Crossman, A. R., and Brotchie, J. M.
(2005). Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned
marmoset model of Parkinson’s disease. Mov. Disord. 20, 403–409. doi:
10.1002/mds.20345
Simola, N., Morelli, M., and Carta, A. R. (2007). The 6-hydroxydopamine model of
Parkinson’s disease. Neurotox. Res. 11, 151–167. doi: 10.1007/BF03033565
Simuni, T., Borushko, E., Avram, M. J., Miskevics, S., Martel, A., Zadikoff, C.,
et al. (2010). Tolerability of isradipine in early Parkinson’s disease: a pilot dose
escalation study. Mov. Disord. 25, 2863–2866. doi: 10.1002/mds.23308
Singh, S., Singh, K., Gupta, S. P., Patel, D. K., Singh, V. K., Singh, R. K., et al.
(2009). Effect of caffeine on the expression of cytochrome P450 1A2, adeno-
sine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl
1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res. 1283, 115–126.
doi: 10.1016/j.brainres.2009.06.002
Singleton, A. B., Farrer, M. J., and Bonifati, V. (2013). The genetics of Parkinson’s
disease: progress and therapeutic implications. Mov. Disord. 28, 14–23. doi:
10.1002/mds.25249
Slevin, J. T., Gash, D. M., Smith, C. D., Gerhardt, G. A., Kryscio, R., Chebrolu,
H., et al. (2007). Unilateral intraputamenal glial cell line-derived neurotrophic
factor in patients with Parkinson disease: response to 1 year of treatment and 1
year of withdrawal. J. Neurosurg. 106, 614–620. doi: 10.3171/jns.2007.106.4.614
Smeyne, R. J., and Jackson-Lewis, V. (2005). The MPTP model of
Parkinson’s disease. Brain Res. Mol. Brain Res. 134, 57–66. doi:
10.1016/j.molbrainres.2004.09.017
Soriano, A., Ventura, R., Molero, A., Hoen, R., Casado, V., Cortes, A., et al. (2009).
Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent lig-
ands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med.
Chem. 52, 5590–5602. doi: 10.1021/jm900298c
Sprenger, F., and Poewe, W. (2013). Management of motor and non-motor symp-
toms in Parkinson’s disease. CNS Drugs 27, 259–272. doi: 10.1007/s40263-013-
0053-2
Srivastava, R., Brouillet, E., Beal, M. F., Storey, E., and Hyman, B. T. (1993).
Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the
rat by prior decortication or MK-801 treatment: a stereological estimate of neu-
ronal loss. Neurobiol. Aging. 14, 295–301. doi: 10.1016/0197-4580(93)90114-Q
St-Pierre, J. A., and Bedard, P. J. (1995). Systemic administration of the
NMDA receptor antagonist MK-801 potentiates circling induced by intras-
triatal microinjection of dopamine. Eur. J. Pharmacol. 272, 123–129. doi:
10.1016/0014-2999(94)00612-B
Stacy, M., Silver, D., Mendis, T., Sutton, J., Mori, A., Chaikin, P., et al. (2008). A
12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson
disease. Neurology 70, 2233–2240. doi: 10.1212/01.wnl.0000313834.22171.17
Stark, A. K., and Pakkenberg, B. (2004). Histological changes of the dopaminergic
nigrostriatal system in aging. Cell. Tissue. Res. 318, 81–92. doi: 10.1007/s00441-
004-0972-9
Steece-Collier, K., Chambers, L. K., Jaw-Tsai, S. S., Menniti, F. S., and Greenamyre,
J. T. (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B
subunit-containing N-methyl-d-aspartate receptors. Exp. Neurol. 163, 239–243.
doi: 10.1006/exnr.2000.7374
Stocchi, F., Rascol, O., Destee, A., Hattori, N., Hauser, R. A., Lang, A. E.,
et al. (2013). AFQ056 in Parkinson patients with levodopa-induced dyskine-
sia: 13-week, randomized, dose-finding study.Mov. Disord. 28, 1838–1846. doi:
10.1002/mds.25561
Striessnig, J., Koschak, A., Sinnegger-Brauns, M. J., Hetzenauer, A., Nguyen, N.
K., Busquet, P., et al. (2006). Role of voltage-gated L-type Ca2+ channel iso-
forms for brain function. Biochem. Soc. Trans. 34, 903–909. doi: 10.1042/BST0
340903
Sulzer, D. (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson’s
disease. Trends. Neurosci. 30, 244–250. doi: 10.1016/j.tins.2007.03.009
Teismann, P., and Ferger, B. (2001). Inhibition of the cyclooxygenase isoen-
zymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model
of Parkinson’s disease. Synapse 39, 167–174. doi: 10.1002/1098-2396(200102)
39:2<167::AID-SYN8>3.0.CO;2-U
The Ninds Net-Pd Investigators. (2006). A randomized, double-blind, futility clin-
ical trial of creatine and minocycline in early Parkinson disease. Neurology 66,
664–671. doi: 10.1212/01.wnl.0000201252.57661.e1
The Ninds Net-Pd Investigators. (2008). A pilot clinical trial of crea-
tine and minocycline in early Parkinson disease: 18-month results. Clin.
Neuropharmacol. 31, 141–150. doi: 10.1097/WNF.0b013e3181342f32
Thomas, A., Iacono, D., Luciano, A. L., Armellino, K., Di Iorio, A., and Onofrj,
M. (2004). Duration of amantadine benefit on dyskinesia of severe Parkinson’s
disease. J. Neurol. Neurosurg. Psychiatry. 75, 141–143.
Thrash, B., Uthayathas, S., Karuppagounder, S. S., Suppiramaniam, V., and
Dhanasekaran, M. (2007). Paraquat and maneb induced neurotoxicity. Proc.
West. Pharmacol. Soc. 50, 31–42.
Tomac, A., Lindqvist, E., Lin, L. F., Ogren, S. O., Young, D., Hoffer, B. J., et al.
(1995). Protection and repair of the nigrostriatal dopaminergic system by
GDNF in vivo. Nature 373, 335–339. doi: 10.1038/373335a0
Traynelis, S. F., Wollmuth, L. P., Mcbain, C. J., Menniti, F. S., Vance, K. M., Ogden,
K. K., et al. (2010). Glutamate receptor ion channels: structure, regulation, and
function. Pharmacol. Rev. 62, 405–496. doi: 10.1124/pr.109.002451
Trevitt, J., Vallance, C., Harris, A., and Goode, T. (2009). Adenosine antago-
nists reverse the cataleptic effects of haloperidol: implications for the treat-
ment of Parkinson’s disease. Pharmacol. Biochem. Behav. 92, 521–527. doi:
10.1016/j.pbb.2009.02.001
Turski, L., Bressler, K., Rettig, K. J., Loschmann, P. A., and Wachtel, H. (1991).
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-
aspartate antagonists. Nature 349, 414–418. doi: 10.1038/349414a0
Varanese, S., Howard, J., and Di Rocco, A. (2010). NMDA antagonist meman-
tine improves levodopa-induced dyskinesias and “on-off” phenomena in
Parkinson’s disease.Mov. Disord. 25, 508–510. doi: 10.1002/mds.22917
Varani, K., Vincenzi, F., Tosi, A., Gessi, S., Casetta, I., Granieri, G., et al. (2010).
A2A adenosine receptor overexpression and functionality, as well as TNF-alpha
levels, correlate with motor symptoms in Parkinson’s disease. FASEB J. 24,
587–598. doi: 10.1096/fj.09-141044
Verhagen Metman, L., Del Dotto, P., Van Den Munckhof, P., Fang, J., Mouradian,
M. M., and Chase, T. N. (1998). Amantadine as treatment for dyskinesias
and motor fluctuations in Parkinson’s disease. Neurology 50, 1323–1326. doi:
10.1212/WNL.50.5.1323
Vernon, A. C., Palmer, S., Datla, K. P., Zbarsky, V., Croucher, M. J., and Dexter, D.
T. (2005). Neuroprotective effects of metabotropic glutamate receptor ligands
in a 6-hydroxydopamine rodent model of Parkinson’s disease. Eur. J. Neurosci.
22, 1799–1806. doi: 10.1111/j.1460-9568.2005.04362.x
Vernon, A. C., Zbarsky, V., Datla, K. P., Croucher, M. J., and Dexter, D. T.
(2007). Subtype selective antagonism of substantia nigra pars compacta Group
I metabotropic glutamate receptors protects the nigrostriatal system against
6-hydroxydopamine toxicity in vivo. J. Neurochem. 103, 1075–1091. doi:
10.1111/j.1471-4159.2007.04860.x
Vissel, B., Krupp, J. J., Heinemann, S. F., and Westbrook, G. L. (2001). A use-
dependent tyrosine dephosphorylation of NMDA receptors is independent of
ion flux. Nat. Neurosci. 4, 587–596. doi: 10.1038/88404
Wachtel, H., Kunow, M., and Loschmann, P. A. (1992). NBQX (6-nitro-
sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl
phosphonic acid) potentiate dopamine agonist induced rotations in substan-
tia nigra lesioned rats.Neurosci. Lett. 142, 179–182. doi: 10.1016/0304-3940(92)
90368-H
Wachter, B., Schurger, S., Rolinger, J., Von Ameln-Mayerhofer, A., Berg, D., Wagner,
H. J., et al. (2011). Effect of 6-hydroxydopamine (6-OHDA) on proliferation of
Frontiers in Neuroscience | Neuropharmacology May 2014 | Volume 8 | Article 113 | 28
Stayte and Vissel Advances in Parkinson’s disease therapeutics
glial cells in the rat cortex and striatum: evidence for de-differentiation of resi-
dent astrocytes. Cell. Tissue. Res. 342, 147–160. doi: 10.1007/s00441-010-1061-x
Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K., Fujimoto, K., Okada, T., et al. (2002).
Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and pro-
motes functional recovery in a rat model of Parkinson’s disease. Gene. Ther. 9,
381–389. doi: 10.1038/sj.gt.3301682
Weidong, L., Shen, C., and Jankovic, J. (2009). Etiopathogenesis of
Parkinson disease: a new beginning? Neuroscientist 15, 28–35. doi:
10.1177/1073858408319974
Wilson, C. J., and Callaway, J. C. (2000). Coupled oscillator model of the dopamin-
ergic neuron of the substantia nigra. J. Neurophysiol. 83, 3084–3100.
Wiltgen, B. J., Royle, G. A., Gray, E. E., Abdipranoto, A., Thangthaeng, N., Jacobs,
N., et al. (2010). A role for calcium-permeable AMPA receptors in synaptic
plasticity and learning. PLoS ONE 5:12818. doi: 10.1371/journal.pone.0012818
Wolf, E., Seppi, K., Katzenschlager, R., Hochschorner, G., Ransmayr, G.,
Schwingenschuh, P., et al. (2010). Long-term antidyskinetic efficacy of
amantadine in Parkinson’s disease. Mov. Disord. 25, 1357–1363. doi:
10.1002/mds.23034
Wright, A., and Vissel, B. (2012). The essential role of AMPA receptor GluR2 sub-
unit RNA editing in the normal and diseased brain. Front. Mol. Neurosci. 5:34.
doi: 10.3389/fnmol.2012.00034
Wu, T., Wang, J., Wang, C., Hallett, M., Zang, Y., Wu, X., et al. (2012). Basal ganglia
circuits changes in Parkinson’s disease patients. Neurosci. Lett. 524, 55–59. doi:
10.1016/j.neulet.2012.07.012
Wullner, U., Testa, C. M., Catania, M. V., Young, A. B., and Penney, J. B. Jr. (1994).
Glutamate receptors in striatum and substantia nigra: effects ofmedial forebrain
bundle lesions. Brain Res. 645, 98–102. doi: 10.1016/0006-8993(94)91642-X
Xu, K., Xu, Y. H., Chen, J. F., and Schwarzschild, M. A. (2002). Caffeine’s neuropro-
tection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no
tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322, 13–16.
doi: 10.1016/S0304-3940(02)00069-1
Yasuda, Y., Shimoda, T., Uno, K., Tateishi, N., Furuya, S., Yagi, K., et al.
(2008). The effects of MPTP on the activation of microglia/astrocytes and
cytokine/chemokine levels in different mice strains. J. Neuroimmunol. 204,
43–51. doi: 10.1016/j.jneuroim.2008.08.003
Youdim, M. B. (2012). M30, a brain permeable multitarget neurorestorative drug
in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
Parkinsonism. Relat. Disord. 18(Suppl. 1), S151–S154. doi: 10.1016/S1353-8020
(11)70047-5
Youdim, M. B., Stephenson, G., and Ben Shachar, D. (2004). Ironing iron out in
Parkinson’s disease and other neurodegenerative diseases with iron chelators: a
lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann.
N.Y. Acad. Sci. 1012, 306–325. doi: 10.1196/annals.1306.025
Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss
is greater in the locus coeruleus than nucleus basalis and substantia nigra in
Alzheimer and Parkinson diseases.Arch. Neurol. 60, 337–341. doi: 10.1001/arch-
neur.60.3.337
Zhang, Z., Miyoshi, Y., Lapchak, P. A., Collins, F., Hilt, D., Lebel, C., et al.
(1997). Dose response to intraventricular glial cell line-derived neurotrophic
factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther. 282,
1396–1401.
Zhou, F. C., Bledsoe, S., andMurphy, J. (1991). Serotonergic sprouting is induced by
dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556, 108–116.
doi: 10.1016/0006-8993(91)90553-8
Zuddas, A., Oberto, G., Vaglini, F., Fascetti, F., Fornai, F., and Corsini, G. U.
(1992a). MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced parkinsonism in primates. J. Neurochem. 59, 733–739. doi:
10.1111/j.1471-4159.1992.tb09429.x
Zuddas, A., Vaglini, F., Fornai, F., Fascetti, F., Saginario, A., and Corsini, G. U.
(1992b). Pharmacologic modulation of MPTP toxicity: MK 801 in prevention
of dopaminergic cell death in monkeys and mice. Ann. N.Y. Acad. Sci. 648,
268–271. doi: 10.1111/j.1749-6632.1992.tb24553.x
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 08 February 2014; accepted: 30 April 2014; published online: 22 May 2014.
Citation: Stayte S and Vissel B (2014) Advances in non-dopaminergic treatments for
Parkinson’s disease. Front. Neurosci. 8:113. doi: 10.3389/fnins.2014.00113
This article was submitted to Neuropharmacology, a section of the journal Frontiers in
Neuroscience.
Copyright © 2014 Stayte and Vissel. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org May 2014 | Volume 8 | Article 113 | 29
